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ABSTRACT 
 
 
Mechanisms of Induced Cell Death in Bluetongue Virus  
Challenged Human Cell Lines 
 
by 
 
 
Justin Darrel Hoopes, Doctor of Philosophy 
 
Utah State University, 2009 
 
 
Major Professor:  Dr. Joseph K.-K. Li 
Department:  Biology 
 
 
 Bluetongue virus (BTV) is a pathogenic member of the Reoviridae family.  
BTV does not cause disease in humans, but is capable of selectively infecting 
and killing certain transformed human cell lines.  Understanding BTV’s 
oncotrophism may lead to new therapeutics for treating cancer.  This study 
focused on the underlying mechanisms of BTV-induced cell death in carcinoma 
cell lines.  It was our hypothesis that BTV infects human carcinoma transformed 
cells, produces mRNA and protein, induces a strong inflammatory response, 
induces mitogen activated protein kinase (MAPK)-based pro-apoptotic signaling, 
inhibits PKB-based signaling, and eventually kills the cell by inducing apoptosis. 
 Three carcinoma cell lines (A498, HEP-G2, and A549) were independently 
infected with BTV.  In each cell line we determined: (1) cell viability over the 
course of infection; (2) BTV induced cytokine expression profile and magnitude of 
expression; (3) BTV viral RNA expression profile and magnitude of expression; 
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(4) BTV viral protein expression profile and magnitude of expression; (5) changes 
in BTV induced cell death and cytokine expression in cells with protein kinase B 
(PKB), p38-MAPK, extracellular receptor kinase (ERK-1/2), stress-activated 
protein kinase (SAPK-JNK), Src kinase, platelet-derived growth factor receptor 
(PDGFR) kinase, epidermal growth factor receptor (EDGFR) kinase, or Janus 
kinase (JAK) activity inhibited; (6) intracellular changes in PKB, p38-MAPK, ERK-
1/2, and SAPK-JNK phosphorylation as a result of BTV infection; and (7) BTV-
induced changes in tyrosine phosphorylation. 
 We determined that BTV infects and kills all three cell lines in a cell line 
dependent manner.  Relative cell death between cell lines was proportional to 
cytokine expression, but inversely proportional to viral protein expression.  Only 
tyrosine kinase inhibitors influenced BTV-induced cell death and cytokine 
expression.  Both A498 and A549 cells constitutively expressed phosphorylated 
PKB and p38 MAPK, of which both were de-phosphorylated during BTV 
infection.  Tyrosine phosphorylation remained active, with elevated tyrosine 
phosphorylation exclusively in infected cells.   
We conclude that BTV-induced cell death and cytokine expression are a 
function of the cell’s response to infection and are directly related through 
intracellular signaling.  These pathways are only partially poly I:C inducible, but 
include PKB and tyrosine kinase signaling. 
(171 pages) 
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INTRODUCTION AND LITERATURE REVIEW 
 
 
INTRODUCTION 
 
 
BTV in the News 
 
On 18 August, 2006, an outbreak of bluetongue virus (BTV) was reported 
in southern Netherlands; the first reported incidence of BTV anywhere in northern 
Europe (IAHD, 2006).  Following confirmation in the Netherlands and the UK, an 
immediate ban on live exports of sheep, cattle and goats and "living products" 
including sperm, cells and embryos was established.  In addition, transportation 
was restricted for all ruminants within 100 kilometers of the incident case (BBC 
News, 2006).  Europe’s International Animal Health Division, a division of the 
Department of Environment Food and Rural Affairs, categorizes BTV among its 
list of high impact diseases of major concern.  Since the initial report on 18 
August, outbreaks of BTV have been reported in France, Luxemborg, and 
Germany.  The causative agent was determined to be serotype 8, the first 
incidence of this serotype anywhere in Europe (BBC News, 2006). 
This report from the Netherlands is an example of the epizootic nature of 
the BTV and the economic impact this virus can have.  Historically, the United 
States has experienced multiple outbreaks of BTV (Ackerman and Giroux, 2006).  
The economic impact of these outbreaks on international trade poses a greater 
threat to the livestock industry than the disease itself (McDill, 2002).  Because of 
this, BTV was listed among the registered agents of the Agricultural Bioterrorism 
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Protection Act (2002).  Economically, BTV is estimated to cost the United States 
$125 million annually in lost trade (Bram et al., 2002).  Because of the recent 
epidemic, and resultant economic impact, BTV is generating greater interest by 
governments, the veterinary industry, and by researchers. 
 
Viral Phylogeny and Epidemiology 
BTV is classified in the Reoviridae family among the Orbivirus genus and 
is the most studied virus within this genus.  The Reoviridae family encompasses 
nine distinct genera of segmented double-stranded RNA (dsRNA) viruses (Joklik, 
1983).  Members of the Reoviridae family are extremely diverse in tropism as 
well as pathology (Urbano and Urbano, 1994).  Generally, members of the 
Reoviridae share a non-enveloped icosahedral capsid approximately 70 nm in 
diameter, a dsRNA genome composed of 10 to 12 segments, incomplete virion 
uncoating, non-polyadenylated 5’ capped mRNA, and viral packaging of all 
proteins necessary for replication (Nibert et al.,1996).  The Orbivirus genus 
includes 14 serogroups based on complement fixation (Borden et al., 1971), 
including viruses such as African hose sickness virus (AHSV), epizootic 
hemorrhagic disease virus (EHDV), and BTV (Verwoerd et al., 1979).  There is 
no common antigen to all serogroups though BTV identification is often hindered 
by cross-reactions with many of these antigenically related viruses (McDill, 
2002).  BTV is the prototype species and the most studied member of this genus 
(Verwoerd et al., 1979).   
Five serotypes of BTV circulate within the United States, while there are 
24 known serotypes worldwide.  The 24 serotypes are classified into three major 
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groupings:  North American, Australian, and African (Gould, 1988b).  The 
endemic U.S. serotypes include 2, 10, 11, 13, and 17, though serotype 1 was 
isolated from a white-tail deer in Louisiana in Nov 2004 (Johnson et al., 2006).  
Gene homology studies suggest serotype 10 is the principle ancestor to the U.S. 
serotypes, while serotype 2 is the most distantly related (Hwang et al., 1993).  
Historically, natural genetic reassortment has been observed only within specific 
groups (Gould, 1988a). 
BTV causes bluetongue disease in both domestic and wild ruminants. 
BTV primarily affects sheep and is most severe in European breeds (Gorman, 
1990).  White-tailed deer and antelope are also very susceptible.  Cattle, goats, 
North American elk, elephants, buffalo, and dromedary camels may also be 
infected by BTV but usually display subclinical symptoms, potentially serving 
more as a reservoir for the virus (American Veterinary Medical Association, 
2006).  BTV is not contagious.  It is only transmissible through an arthropod 
vector, most commonly biting midges in the genus Culicoides (Erasmus, 1975).  
As a result, disease outbreak and transmission are associated with Culicoides 
habitat and not animal habitat or behavior.  While habitat and behavior have little 
impact, bluetongue disease severity is heavily dependent on the species, breed, 
age, health status, multiplicity of infection (MOI) and infecting viral serotype (Roy, 
1992). 
 
Disease Pathology 
The hallmarks of bluetongue disease include the production of primary 
lesions (inflammation and ulceration of mucosal surfaces) around the mouth 7-10  
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Fig. 1-1.  A BTV-infected 
sheep from northern 
Europe.  Bluetongue 
disease in sheep is 
characterized by fever, 
depression, emaciation, 
cyanosis of the tongue, and 
swelling of the muzzle, 
eyelids, and ears.  Photo 
courtesy of the Food and 
Agriculture Organization of 
the United Nations. 
 
days post infection (P.I.) and cyanosis of the tongue (Spruell, 1905).  Discoloring 
of the tongue is due to oxygen deprivation caused both by inflammatory capillary 
constriction as well as disseminated intravascular coagulation caused by viral-
induced endothelial damage (Howerth and Tyler, 1988).  In sheep it causes 
soremuzzle, characterized by fever (up to 107.6 F) as well as depression, 
emaciation, and swelling of the muzzle, eyelids, and ears (Hardy and Price, 
1952).  A sheep displaying the symptoms of bluetongue disease is shown in Fig. 
1-1.  Severe inflammation can also compromise mobility and respiration.  Fetal 
abortion usually occurs if ewes are infected during the first trimester of 
pregnancy.  Observed mortality rates have been as high as 75% in some 
outbreaks (Manso-Ribeiro et al., 1957).  If death does occur it is usually within 8 
to 10 days as a result of pharyngeal lesions and/or heart failure (Mahrt and 
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Osburn, 1986).  Surviving animals can often experience hair loss, sterility, 
cracked hooves and muzzle, as well as delayed growth (Jeggo et al., 1983). 
 
BTV Virion Structure 
BTV is a nonenveloped icosahedral virus with two capsid layers, arranged 
in a T3 structural morphology around the inner core (Els and Verwoerd, 1969).  
The total virus particle is around 68-70 nm wide (Martin and Zweerink, 1972).  
The genome of BTV consists of 10 dsRNA segments (Verwoerd, 1970; Verwoerd 
et al., 1970), ranging from 822 to 3954 base pairs in size, for a total genome of 
1.9 X 104 base pairs (Verwoerd et al., 1970).  The genome segment and size of 
each protein can be seen in Table 1-1.  The names of each gene are derived 
from their electrophoretic motility, classified into large (L), medium (M), and small 
(S).  Each gene encodes a specific protein, except for the smallest gene segment 
(S4), which encodes two proteins via an overlapping second reading frame 
(Mertens and Sangar, 1985).  Of the 11 proteins, 7 are found within the structure 
of the virus, while 4 facilitate the replication cycle, but are not included within the 
viral particle itself.  The exact functions of these non-structural proteins are 
unknown.  A schematic of the virus can be seen in Fig. 1-2.  The inner core is 
composed of viral proteins (VP)1, VP4, and VP6 closely associated with viral 
dsRNA.  Surrounding this is the inner capsid composed of VP3 and VP7.  The 
outer capsid is composed of VP2 and VP5 non-covalently associated with the 
inner capsid (Verwoerd et al., 1972; Huismans et al., 1987b). 
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TABLE 1-1 
 
Bluetongue Virus Gene Segments, Encoded Proteins, 
Location Within Virion, and Putative Function. 
 
Genome 
Segment 
Base 
Pairs 
Encoded 
protein Virion location Function 
L1 3954 VP1 Inner core RNA polymerase/transcriptase 
L2 2926 VP2 Outer shell Structural – Adhesion 
L3 2772 VP3 Core Structural 
M1 2011 VP4 Inner core 5’- mRNA capping enzyme 
M2 1639 VP5 Outer shell Structural – hemeagglutination 
M3 1770 NS1 Non-structural Virion transport 
S1 1156 VP7 Core Structural 
S2 1123 NS2 Non-structural mRNA binding  
S3 1046 VP6 Inner core RNA helicase 
S4 822 NS3/3A Non-structural Viral progeny release 
 
 
 
FIG. 1-2. BTV virion 
structure.  The virion is 
composed of 10 dsRNA 
segments packaged 
along with VP1, VP4, and 
VP6 within a VP3/VP7 
capsid.  The inner 
VP3/VP7 capsid is 
subsequently covered in 
a VP2/VP5 outer capsid.  
The virus is not 
enveloped.  Each viral 
protein is indicated on the 
diagram by their 
respective number. 
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BTV Genome and Proteins 
The largest viral protein is VP1 (Huang et al., 1995).  Derived from the L1 
gene, VP1 is a subcore component which functions as an RNA-dependent RNA 
polymerase, serving dual roles as transcriptase and replicase (Roy, 1992; Boyce 
et al., 2004).  In vitro replicase activity shows little specificity for BTV genes, 
suggesting specificity is derived from its association with VP4 and VP6 (Boyce et 
al., 2004).  After endocytosis and upon removal of the outer capsid layer, VP1 
begins production of mRNA from within the core particle (Watanabe et al., 1968; 
Grimes et al., 1998).  Following mRNA production, VP1 replicates new genomic 
dsRNA from previously synthesized mRNA by strand displacement (Roy, 1992). 
VP2 and VP5, derived from the L2 and M2 genes respectively, constitute 
the outer capsid layer.  VP2 represents the major variable epitope which defines 
serotype (Kahlon et al., 1983) and is the recognition marker responsible for 
endocytosis (Huismans and Erasmus, 1981).  Purified VP2 displays 
hemagglutinin activity through binding to glycophorin A, a sialoglycoprotein 
component of erythrocytes (Hassan and Roy, 1999) suggesting VP2 may be 
responsible for transmission by Culicoides.  At present, the cellular recognition 
region on VP2 has not been identified, though Hassan and Roy (1999) suggest 
the receptor is likely a glycoprotein.  Gene sequences show that there are 16 
conserved cysteine residues present (Huismans and Van Dijk, 1990), though 
VP2 does not appear to be covalently linked to VP5 (Verwoerd et al., 1972). 
VP5 is more structurally conserved than VP2 (Mecham et al., 1986) likely 
due to VP5’s association with the core proteins (Verwoerd et al., 1972).  VP5 is 
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sometimes referred to as GP5 because it is glycosylated with short unbranched 
carbohydrates (Yang and Li, 1993).  VP5 can bind to different agglutinating 
lectins, probably contributing to the hemeagglutination properties of BTV.  Its 
main function appears to be membrane permeabilization of the endosomal 
compartment facilitating release of uncoated virus into the cytoplasm (Hassan et 
al., 2001).  VP5 shares structural features with class I fusion proteins of 
enveloped viruses (Forzan et al., 2004), which may give BTV its ability to 
associate with and permeabilize membranes.  Extracellular treatment of 
mammalian cells with recombinant VP2 and VP5 together can result in apoptosis 
(Mortola et al., 2004), though the mechanism or function of this is currently 
unknown. 
VP3 and VP7, derived from L3 and S1 genes respectively, together make 
up the inner capsid layer.  The VP3 and VP7 sequences are highly conserved 
among all serotypes (Huismans and Erasmus, 1981).  Both are very hydrophobic 
(Yu et al., 1988; Huismans and Van Dijk, 1990) and can assemble in an alternate 
host without other viral proteins present (French and Roy 1990; Kar et al., 2005).  
VP7 exists as a trimer which is inserted into an organized VP3 dimer matrix 
(Burroughs et al., 1995), as shown in Fig. 1-2.  VP7 is the most abundant of BTV 
proteins found within the viral particle (Huismans et al., 1987b).  The N-terminal 
region of VP7 has been shown to protrude to the surface of the outer capsid 
(Hyatt and Eaton, 1988), conveying the serogroup-specificity of BTV (Wang et 
al., 1996).  Because of this, VP7 has generated great interest as a target for a 
universal BTV vaccine.  It is the only protein for which the crystal structure is 
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known (Grimes et al., 1995).  BTV can infect insect cells once the inner capsid is 
assembled (through VP7’s RGD tripeptide motif) but cannot infect mammalian 
cells until the outer capsid is assembled (Tan et al., 2001). 
VP4 (M1 gene product) is a highly conserved inner core protein present at 
5-10 copies per virion (Huismans and Van Dijk, 1990). VP4 together with VP1 
attach to the underside of VP3 within the viral core in (Nason et al., 2004).  VP4 
has been shown to nonspecifically bind single stranded RNA (ssRNA) (Huang et 
al., 1993) via an essential leucine-zipper motif near the c-terminus of the protein 
(Ramadevi et al., 1998b).  VP4 is also an NTP hydrolase (Ramadevi and Roy, 
1998), RNA 5’-triphosphatase (Martinez-Costas et al., 1998), inorganic 
pyrophosphatase (Martinez-Costas et al., 1998), a type 1 and type 2 methylase 
(Ramadevi et al. 1998a), as well as a guanylyltransferase (Huang et al., 1993).  
In short, VP4 performs all of the reactions necessary for complete 5’ guanine 
capping of viral encoded messenger RNA (mRNA), prior to translation.   
Gene S3 encodes VP6, the last of the three minor inner core proteins.  
Each virion carries approximately 36 copies of this protein (Huismans and 
VanDijk, 1990).  VP6 has nucleoside triphosphatase, RNA binding, and helicase 
activity (Stauber et al., 1997).  VP6 is highly conserved among serotypes and is 
the most polar of all the BTV proteins (Fukusho et al., 1989).  ATP binding has 
been linked to the conserved AXXGXGK(110)V motif (Kar and Roy, 2003).  VP6 
contains multiple nucleic acid binding domains (Hayama and Li, 1994) and 
probably functions within the core virion as a dsRNA stabilizer (Roy, 1989; Roy et 
al., 1990) and during transcription as an RNA-helicase (Roy, 1996). 
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Gene M3 encodes non-structural protein, NS1.  It contains 552 amino 
acids and is predicted to be 64 kDa in size (Urakawa and Roy, 1988).  The M3 
gene was originally designated the M2 gene.  M2 is now designated to encode 
VP5.  NS1 is the most abundantly produced viral protein (Huismans and Van 
Dijk, 1990).  It is highly conserved among BTV serotypes, though it shows only 
around 50% sequence conservation with other Orbiviruses (Huismans and 
Cloete, 1987).  Its function within the cell is unknown; however, within the viral 
inclusion body (VIB) it has been suggested to act as a molecular chaperone to 
prevent core particle assembly before VP1, 4, 6 and the genome are 
incorpoarated (Hewat et al., 1992).  Upon entry into the cytoplasm, the NS1 
protein will spontaneously polymerize into tubules (Huismans, 1979; Huismans 
and Els, 1979) between 50 and 68 nm in diameter with a 9 nm banding 
(Huismans and Els, 1979; Hewat et al., 1992).  The tubules associate with the 
intermediate filaments of the cytoskeleton (Eaton et al., 1988).  The presence of 
NS1 tubules is one of the most notable pathological conditions of BTV infection 
observed under a microscope (Lecatsas, 1968).  The function of these tubules 
has not been established though they are probably involved in viral transport to 
and from VIBs (Eaton et al., 1988).  
Encoded by the S2 gene, NS2 is produced abundantly within the cell.  
NS2 alone forms inclusion bodies in transfected insect cells (Thomas et al., 
1990).  Within inclusion bodies, NS2 binds ssRNA non-specifically, but does not 
bind to dsRNA (Huismans et al., 1987a; Uitenweerde et al., 1995).  Three RNA 
binding domains have been identified in this protein (Fillmore et al., 2002).  NS2’s 
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proposed role is to associate with newly formed mRNA to protect it from 
destruction prior to its encapsidation.  NS2 may also be responsible for ensuring 
that only the 10 distinct mRNAs are condensed prior to dsRNA synthesis during 
genome replication and viral morphogenesis (Eaton et al., 1988; Lymperopoulos 
et al., 2006). 
NS2 is the only known phosphorylated BTV protein (Huismans et al., 
1987a).  Phosphorylation occurs on two serine residues at positions 249 and 259 
(Modrof et al., 2005).  NS2 phosphorylation can occur in vitro (Huismans et al., 
1987a) but unlike rotavirus NSP2, a functional homolog, NS2 does not 
autophosphorylate (Taraporewala et al., 2001).  Instead, cellular kinases are 
necessary for phosphorylation.  In addition, recombinant NS2 displays nucleotidyl 
phosphatase activity (Horscroft and Roy, 2000) as opposed to NSP2’s NTPase 
only activity (Taraporewala et al., 2001).  Phosphorylation of NS2 somewhat 
reduces affinity for ssRNA, but appears essential for the formation of VIBs 
(Modrof et al., 2005).   
S4, the smallest gene encodes the NS3 and NS3a proteins.  The gene 
contains two in phase open reading frames (ORFs); the primary ORF starting at 
base position 20 and the second ORF starting at base position 59 (Van Dijk and 
Huismans, 1988).  The exact functions of either protein is unknown, but they 
have been shown to be associated with cellular membranes and hydropathy 
plots show two distinct hydrophobic membrane spanning domains at amino acids 
118 to 141 and 162 to 182 (Huismans and Van Dijk, 1990).  NS3/3a can be 
found naturally in both n-linked glycosylated and non-glycosylated forms (Wu et 
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al., 1992).  Glycosylation occurs at an asparagine in position 150 on the protein 
(Bansal et al., 1998).  Hyatt et al. (1993) suggested NS3 facilitates the release of 
virus by causing local lesions in the cell membrane.  NS3 and NS3a also contain 
the characteristic P(T/S)AP and PPXY membrane binding motifs found at residus 
7-10 on the p6 region of the human HIV-1 GAG protein (Garrus et al., 2001) and 
in membrane-associated proteins of filo-, rhabdo-, and oncoretroviruses (Craven 
et al., 1999; Harty et al., 2000).  The presence of these motifs also suggest a role 
for NS3/3a in progeny release through recruiting cellular proteins.  Wirblich et al. 
(2006) have recently shown NS3 to recruit Tsg101, a component of the 
ubiquitinization ESCRT-1 complex, though this motif, and that depletion of 
Tsg101 through RNA interference inhibits the release of BTV from infected cells.  
NS3, through yeast two-hybrid studies, has also been shown to associate with 
cellular protein p11 (calpactin light chain) though an N-terminal domain (Beaton 
et al., 2002).  This protein is part of the annexin II complex involved in exocytosis.   
NS3 also binds VP2 though a c-terminal domain (Beaton et al., 2002), 
suggesting NS3 may bridge association between assembled viral particles and 
exocytosis machinery.  NS3 has also recently been shown to have viroporin like 
properties (Han and Harty, 2004). Viroporins are a group of hydrophobic 
transmembrane proteins that can form hydrophilic pores in a lipid bilayer.  The 
formation of these pores would allow release of progeny virus by direct 
penetration of the cell membrane.  Even though the functions of NS3 have not 
been definitively stated, it is certain that NS3 plays an important role in the 
release of viral progeny. 
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Measuring BTV RNA and Protein Expression 
The 10 genes described previously all play an essential role in replication 
and changes in their expression can affect replication rates and fitness.  Various 
methods have been developed to measure BTV RNA and protein expression.  
One way BTV RNA can be detected and quantitated is through quantitative real 
time PCR (qRT-PCR) (Buccambusco, 2005).  This process involves purifying 
total RNA from a sample, followed by reverse transcription of RNA to 
complimentary DNA (cDNA) and subsequent PCR.  The PCR reaction takes 
place in the presence of Cyber Green, a flourescent intercalating dye.  Primers 
specific to each viral gene lead to specific amplification of the target gene.  
Amplification of the target gene results in more Cyber Green intercalation leading 
to a higher fluorescent signal.  This signal can be used to quantify the amount of 
each viral gene present in the sample. 
Available methods for quantifying BTV protein are not as automated as 
RT-PCR.  BTV viral protein is measured by Western blot.  Western blotting is the 
process of probing for a specific protein using enzyme labeled antibodies-specific 
to the protein of interest.  Sample is resolved by polyacrylamide gel 
electrophoresis then transferred to a polyvinylidene fluoride (PVDF) membrane.  
The membrane is then blocked to prevent non-specific binding and incubated 
with BTV specific antibody.  Antibody binding is detected by the addition of the 
linked enzyme’s substrate. 
When antibodies to specific BTV proteins are not commercially available, 
antisera is used instead.  BTV antiserum reacts to the major antigenic epitopes 
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within the viral capsids, predominantly VP2 followed by VP7, VP5, and VP3, 
respectively. 
 
Viral Replication Cycle 
BTV is a fully infectious virus, meaning it carries all of the proteins 
necessary to begin replication.  This is necessary as the genome is dsRNA which 
must be processed by specialized proteins.  BTV primarily infects endothelial 
cells of the vascular wall, in vivo.  Utilizing VP2 attachment protein, the virus is 
taken into clathrin coated endosomes by endocytosis (Sturzenbecker et al., 
1987).  In tissue culture, adsorption usually occurs within 20 minutes P.I. (Howell 
et al., 1967). Within the endosome, as the pH is lowered, VP2 is lost and VP5 
binds to the endosomal membrane where it promotes viral penetration into the 
cytoplasm (Dales, 1973; Tyler et al., 1985).  Once the outer capsid has been 
removed, the RNA-dependent RNA polymerase (VP1) becomes activated (Van 
Dijk and Huismans, 1980).  The core particle then binds cellular intermediate 
filaments (Eaton and Hyatt, 1989) and begins to produce and release mRNA into 
the cytoplasm (Bowne and Jochim, 1967).  New mRNA is 5’ guanidine capped 
(Furwichi and Shatkin, 1977) by VP4 (Huang et al., 1993), but not 
polyadenylated.  This mRNA is used for translation and later condensed by NS2 
(Zweerink et al., 1971) into viral inclusion bodies where it associates with VP3 
dimers (Kar et al., 2004).  Once associated with VP3, mRNA is then converted 
into viral genomic dsRNA (Acs et al., 1971). 
When all the necessary components are gathered, morphogenesis of the 
inner core takes place within the VIB (Morgan and Zweerink, 1975; Zarbl et al., 
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1980).  After exiting the VIB, VP2, and VP5 are added to form the outer capsid.  
From there, virulent particles may either stay in the cell (Howell and Verwoerd, 
1971) or be released through the aid of NS3/3a.  Release can occur through 
direct penetration of the cell membrane (Hyatt et al., 1993) or though budding 
(Bowne and Ritchie,1970; Foster and Jones, 1979).  Both events have been 
seen, though viral release in mammalian cells through budding is noted in less 
than 5% of cases.  If virus is released by budding, the membrane is lost shortly 
thereafter. 
 
Non-Ruminant Host Relationship 
BTV is known to infect a broad diversity of host species and the severity of 
disease is just as diverse across these species, though bluetongue disease does 
not occur in humans and mice. There is a rare BTV strain which has been 
reported to replicate in mice (Brewer and Osburn, 1998) though this has yet to be 
independently confirmed.  Species specificity is less clear in vitro where BTV can 
replicate in a wide variety of cell lines (McPhee et al., 1982).  It is normally 
cultured in hamster kidney (BHK-21) cells or in African green monkey kidney 
(Vero) cells.   
Challenge of some human cell lines with BTV has recently been shown to 
induce apoptotic cell death (Xiao et al., 2004).  This observation may be related 
to the transformed nature of the cells and other experiments have shown that 
BTV infection of human primary cells does not cause cell death (Hu et al., 2008).  
These findings suggest BTV may be an oncolytic virus, meaning the virus 
replicates more efficiently in cancer cells than in normal cells (Guo et al., 2005).  
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Cancer cells often make a good host for viruses for reasons that include mutated 
tumor suppressor genes and inactivated antiviral interferon pathways (Myers et 
al., 2005; Galanis et al., 2005).  The mechanisms which allow BTV’s selective 
oncolysis are unknown. 
 
Innate Immunity 
One mechanism by which BTV can induce cell death is through activation 
of innate immunity.  Innate immunity includes viral defenses which are intrinsic to 
each cell independent of the host immune system.  Innate defenses to dsRNA 
include toll-like receptors (TLRs), type I interferons (IFNα and IFNβ), and RNA-
interference. 
TLRs are molecular pattern recognition receptors (Aderem and Ulevitch, 
2000).  There are currently 13 recognized TLRs, each having affinity for a 
specific pattern commonly expressed by pathogens (Takeda et al., 2003).  For 
example, lipopolysaccharide (LPS) is recognized by TLR4 leading to activation of 
cells and expression of numerous inflammatory cytokines (Ståhl et al., 2006).  
TLRs display differential tissue and cell expression highly dependent on the 
function of the receptor (Hopkins and Sriskandan, 2005).  Though each TLR has 
its own specific function, virtually all utilize the same MyD88 cell signaling 
pathway leading to inflammation.  The exception is TLR3, which utilizes a 
MyD88-independent signaling pathway (Meylan et al., 2004).  TLR signaling is 
graphically represented in Fig. 1-3. 
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FIG. 1-3.  Toll-like receptor 
(TLR) signaling.  TLR’s are 
innate pattern recognition 
receptors which activate host 
defense mechanisms through 
MyD88-dependent and -
independent pathways.  Double 
stranded RNA is recognized by 
the TLR3 receptor in the 
endosome which can induce 
antiviral proteins and 
inflammatory mediators. 
 
TLR3 specifically recognizes dsRNA (Hopkins and Sriskandan, 2005). 
This innate receptor is of particular interest with respect to BTV because the 
genome of BTV is dsRNA.   Double-stranded RNA does not naturally exist in 
mammalian cells.  If present, it is treated as a product of infection with an RNA 
virus.  In the case of ssRNA viruses, dsRNA is generated as part of the genomic 
replication process as the RNA-dependent RNA polymerase makes replicate 
copies of the viral genome.  The genome will be packaged as ssRNA, but dsRNA 
is an intermediate as well as a byproduct of incomplete packaging.   
Unlike ssRNA viruses, BTV’s dsRNA genome can induce innate immunity 
through TLR3 or through cytoplasmic receptors such as retinoic acid-induced 
protein I (RIG-I) and melanoma differentiation-associated gene-5 (MDA-5) 
(Andrejeva et al., 2004; Yoneyama et al., 2004; Kato et al., 2005; Gitlin et al., 
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2006) to cause cell death and cytokine expression (Hoebe et al., 2004), even 
without viral replication. 
In addition to avoiding TLR’s and cytoplasmic receptors, dsRNA must also 
avoid degradation of viral mRNA caused by activation of the cellular RNA-
induced silencing complex (RISC) and simultaneous activation of the type I 
interferon response (Saha et al., 2006).  RISC formation is part of the RNA 
interference (RNAi) process first characterized in the nematode worm 
Caenorhabditis elegans (Fire et al., 1998).  Double-stranded RNA was later 
shown to induce the formation of the RISC complex which would target and 
destroy mRNA complementary to the dsRNA sequence (Sledz and Williams, 
2005).   
Double stranded RNA can also induce type I interferons which are 
autocrine and paracrine cytokines that induce transcription of numerous antiviral 
genes (Theofilopoulos et al., 2005).    Both RNAi and type I interferon production 
are defense mechanisms intended to prevent the virus from completing 
replication.  Even though BTV attempts to protect its dsRNA genome by 
sequestering it in the viral core particle during transcription, it is particularly 
vulnerable to this mechanism because dsRNA is prevalent within the cell at every 
stage of infection (Grimes et al., 1998). 
 
Types of Viral-Induced Cell Death 
BTV induces both apoptotic and necrotic cell death.  Apoptosis is tightly 
controlled, programmed cell death.  Necrosis encompasses any other type of cell 
death (Kerr et al., 1972).  Apoptosis is specifically, an energy-dependent, 
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asynchronous, genetically controlled process by which unnecessary or damaged 
single cells self-destruct upon apoptotic activation (Martin, 1993; Earnshaw, 
1995).  One major characteristic of apoptosis is that an apoptotic cell has little 
impact on surrounding cells (Bar, 1996), while necrosis is characterized by 
widespread damage and inflammation (Kam and Ferch, 2000).  This is because 
reactive oxygen species and toxic proteins are released from necrotic cells, 
causing localized tissue damage.  In the animal host, BTV infection often causes 
secondary necrosis as a result of severe inflammation and vasoconstriction 
(DeMaula et al., 2002a; DeMaula et al., 2002b), but in mammalian cell culture, 
infection usually results in apoptosis (Nagaleekar et al., 2007).   
Apoptosis is used by the host to regulate, renew, and protect itself.  It is 
particularly important in viral host defense.  This is because a virus relies on the 
cellular machinery to complete replication and a cell which undergoes apoptosis 
can no longer be used by the virus to replicate.  If the apoptotic system is 
compromised, the host is more susceptible to viral infection as well as many 
other diseases, including cancer (Osaki et al., 2004).  Some viruses directly 
inhibit apoptosis in their target cells to prolong host cell life thereby prolonging 
replication.  Examples include Papilloma virus and Adenovirus which both 
encode p53 inhibitors (Zekri et al., 2006; Ying et al., 2007).  P53 is an essential 
component in regulating the cell cycle as well as recombination after genomic 
damage.  When p53 is inhibited, the cell continually replicates and is unable to 
undergo apoptosis (Zekri et al., 2006).  
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On a systemic level there are three phases to apoptosis (Arends and 
Wyllie, 1991).  First, the cell detaches from adjacent cells and the genomic DNA 
is digested by specific endonucleases and packaged into organelles (Wyllie, 
1997).  Second, the organelles are released as membrane-bound vesicles to be 
recycled by neighboring cells.  Last, the remaining apoptotic body is 
phagocytosed by myeloid cells (Wyllie, 1997).   
Apoptotic stimuli are broadly categorized into four major groups; including 
DNA damage; activation of death receptors (Fas receptor, TNF receptor); 
stimulation of apoptotic pathways (kinase inhibitors); and damage by UV, heat, or 
peroxides (Kam and Ferch, 2000).  Inflammation is generally not a product of 
apoptosis though some transcription factors associated with viral-induced 
apoptosis are also associated with cytokine expression (Heylbroeck  et al., 
2000).   
 
BTV-Induced Cytokine Expression 
Within the body, an infected cell will recruit the help of the systemic 
immune system and send a warning to neighboring cells to minimize viral spread.  
This is done through the secretion of cytokines.  The mechanisms of cytokine 
induction are diverse and often dependent on the infecting agent.  The effects of 
cytokine induction are just as diverse as the mechanisms of induction. 
Cytokines are hormone-like proteins produced by nearly all cells.  They 
are the predominant mode of communication within the immune system.  
Through cytokines, the immune system regulates stem cell differentiation (Bishop 
et al., 2002), inflammation (Arai et al., 1990), angiogenesis (Carmeliet, 2000), as 
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well as many other events.  Correspondingly, aberrant cytokine expression is 
also often involved in progression and pathogenesis of disease (Whicher and 
Evans, 1990).   
Studying cytokines provides insight into how a cell is responding to 
infection and how the immune system as a whole is managing the infection.  
Cytokines often perform multiple functions and regularly share receptors (Akira et 
al., 1990).  A single cytokine can elicit one effect on one cell type, a different 
effect on another cell type and a completely different response when 
administered concomitantly with other cytokines (Akira et al., 1990).  This 
diversity of activity allows the immune system to control a great variety of events 
with a relatively small repertoire of signaling agents.  This diversity also makes 
interpreting the effects of cytokine expression very difficult.   
In the past, there have been few cytokine studies on BTV infection.  This 
is due predominantly to the limited availability of testing materials for ruminant 
species.  The use of RT-PCR has allowed researchers to do limited cytokine 
studies on an mRNA expression level (DeMaula et al., 2002a; DeMaula et al., 
2002b).  Though not as accurate as protein based tests in determining cytokine 
concentrations, mRNA studies have provided some information about the native 
host cytokine response to BTV infection. 
Within native hosts, BTV infection results in severe pathological effects, 
including prominent swelling systemically, hemorrhaging, and inflammation-
induced necrosis (Spruell, 1905; Chiang et al., 2006; DeMaula et al., 2002a).  
DeMaula et al. (2002a) found that BTV infection of ovine lung microvascular 
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endothelial cells (ECs) showed increased transcription of genes encoding IL-1β 
and IL-8, but little IL-6.  Transcription of these same genes was markedly higher 
in bovine lung microvascular ECs.  These differences between sheep and cattle 
are significant when considering that ovine ECs had lower incidence of infection 
and produced significantly less virus than did bovine ECs (DeMaula et al., 2001), 
but have much higher rate of mortality. 
 These experiments show that cytokine expression from infected cells in 
natural ovine and bovine hosts is greatly elevated and consistent with 
inflammation, though the diversity of cytokines tested was small.  Recently 
Chiang et al. (2006) performed cytokine mRNA testing in human endothelial cells 
infected with BTV-10 and found mRNA expression increased for IL-1β, IL-6, IL-8, 
and TNFα.  They also found that the stimulation of cells with 
polyinosinic:polycytidilic acid (poly I:C) resulted in expression of the same 
cytokines, suggesting that the cause of expression in these cells is due to innate 
immunity to dsRNA. 
There are four classes of cytokines which can be observed in BTV-
infected human carcinoma transformed cells.  These include inflammatory 
cytokines, chemokines, TH1 type differentiators, and angiogenesis factors.  
Inflammatory cytokines are those which promote inflammation at the site of 
infection.  Chemokines are a class of cytokines which are chemotactic for 
specific lymphocytes (Baggiolini et al., 1997).  TH1 differentiators are cytokines 
which promote TH1 type T-cell activation as opposed to TH2 type activation.  
(Clerici and Shearer, 1993).   
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The last set of cytokines are promoters of angiogenesis.  Angiogenesis is 
the process of creating these new blood vessels; and thus, it is an important 
component of human growth.  As the body grows, the demand for oxygen 
increases.  To accommodate for greater demand, new blood vessels must be 
constructed.  This is a complex process incorporating breakdown of old tissue, 
cleanup of digested tissue, and formation of new vascular endothelial cells in its 
place (Carmeliet, 2000).  Angiogenesis plays a critical role in tumor progression 
as well because the tumor’s oxygen demands increase dramatically the larger 
the tumor and the more aggressively the tumor is growing (Carmeliet and Jain, 
2000; Patan, 2004).  BTV infection may inhibit angiogenic factor expression 
which would affect the tumor’s ability to grow. 
 
Measuring Cytokine Expression 
Cytokine expression is determined by either quantifying cytokine mRNA 
using RT-PCR or cytokine protein by reporter-linked immunoassay.  The most 
accepted immunoassay is a sandwich (capture) ELISA (Knight et al., 2004).  This 
process uses two antibodies.  One antibody is bound to a solid phase (i.e. micro-
well plate) and then incubated with sample.  As the sample is incubated, 
cytokines in solution are captured by the anchored antibody.  Following this, each 
well is incubated with a second enzyme-linked antibody.  The second antibody 
binds to a different region on the cytokine.  This binding is detected by monitoring 
the activity of the attached enzyme.  Enzyme activity is proportional to the 
amount of cytokine present in the sample.  One of the best ways to improve 
interpretation is to assay for multiple cytokines (Knight et al., 2004; Leng et al., 
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2008).  The profile of cytokine type and concentration helps to generate a clearer 
picture of the cellular response as well as the underlying cell signaling taking 
place.  Conventional ELISAs, while allowing the researcher to test many samples 
at one time, can test only one type of cytokine in a single test.  This makes 
cytokine profiling costly with respect to time, reagents, and sample volume.  The 
expense of these factors makes multiplexed assays the preferred choice for 
profiling.  Multiplex formats have included fluorescent bead-based assays as well 
as printed arrays (Morgan et al., 2004).  Both methodologies allow the researcher 
to simultaneously measure multiple cytokines in a relatively small volume. 
 
Intracellular Signaling During BTV Infection 
Fundamental to any biological system is accurate communication.  A 
biological system as a whole can communicate through various signals including: 
neuronal signals, chemical hormones, cytokines, and contact.  Accurate 
intracellular communication is just as important.  Within a cell, signals from the 
environment must be relayed through the membrane and then throughout the 
cell.  This is necessary for the cell to properly respond to its environment.  In 
addition, intracellular signals must be passed to the nucleus for proper regulation 
of gene expression.  Finally, changes in gene activity or demand must be relayed 
to the rest of the system and properly accounted for in order to keep the system 
in homeostasis.  When communication pathways are disrupted, pathology 
inevitably follows. 
The cell is analogous to the modern automobile; equipped with sensors 
throughout the entire system, ready to notify the driver of any potentially 
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deleterious condition.  Likewise, the cell employs a brigade of regulatory 
molecules responsible for monitoring and reporting the extracellular and 
intracellular environment.  Also like the automobile, a simple change in one 
process, if not properly identified and accounted for can lead to greater problems. 
The regulatory molecules discussed above are collectively classified as 
signaling molecules, with some responsible for detecting changes and others 
responsible for relaying messages to the proper system.  Signaling molecules 
are a large and diverse group of proteins, but even with a large assortment of 
signaling proteins, the cell often utilizes the same protein in multiple signaling 
pathways and regularly cascades signals via multiple messengers (Kornblau et 
al., 2006; Chang and Karin, 2001; Pearson et al., 2001).  The use of the 
cascading process allows the signal to be rapidly amplified and disseminated 
through multiple systems, such that small triggers can induce dramatic changes.  
Cascading also means slight alterations in the makeup of the signaling 
framework can have dramatic end results.  It also makes it more difficult for 
researchers to distinguish and discern signaling pathways. 
The most common way signals are relayed along the cascade is through 
reversible phosphorylation (Johnson and Lewis, 2001).  The regulation of action 
by reversible phosphorylation was first discovered in 1952 by Edwin G. Krebs 
(Krebs, 1981) with the recognition that glycogen phosphorylase was reversibly 
regulated by phosphorylation.  Though phosphorylation was first discovered in 
eukaryotes, bacteria were later shown to utilize similar phosphorylation signaling 
(Deutscher and Saier, 2005).  Since its first discovery, scientists have discovered 
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500+ kinases, but have mainly succeeded in revealing the complexity of signal 
transduction and regulation (Manning et al., 2002). 
Phosphorylation signals are relayed by transferring a phosphoryl group 
from ATP to the hydroxyl group of the amino acid.  Because of the need for a 
hydroxyl group, there are only three candidate amino acids for phosphorylation: 
serine, threonine, and tyrosine (Johnson et al., 2001).  Once covalently attached, 
the protein is referred to as a phospho-protein.  Phosphate groups are 
transferred to proteins by kinases and removed by phosphatases (Mumby and 
Walter, 1993).  Protein kinases make up the largest family of genes in eukaryotes 
(Rubin et al., 2000; Lander et al., 2001).  The family is classified into three types:  
those which can phosphorylate serine and threonine, those which can 
phosphorylate tyrosine, and those which can phosphorylate any of the three 
(Kitamura et al., 1998; Hubbard and Till, 2000; Cobb and Goldsmith, 1995).  
Phosphorylation occurs after the protein has been folded, restricting 
phosphorylation sites to the surface of a protein.   
The impact of phosphorylation is different for every protein, with effects 
dependent on the site(s) of phosphorylation.  It is not uncommon for a protein to 
have multiple phosphorylation sites, with the pattern of phosphorylation defining 
the activity of the protein (Mayo et al., 2005; Xie et al., 2001).   
Because of the import of intracellular signaling to homeostasis, aberrant 
intracellular signaling often leads to disease.  Cancer is commonly attributed to 
mutations in apoptotic and cell cycle related signaling.  For example, the protein 
kinase Ras is a known oncogene (Bos, 1989).  Normally, it is a GTPase involved 
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in regulating various signaling pathways.  One of the pathways it regulates is the 
MAPK pathway.  When mutated to an overactive state, Ras can induce 
constitutive activation of the cell cycle causing cancer (Lodish et al., 2000). 
In cases where cancer is the result of changes in intracellular signaling, 
treatment can be very complex because inhibition of the mutated kinase can 
have consequences on other known and unknown pathways.  Even so, there are 
cancer drugs on the market which are specific kinase inhibitors (Reuter et al., 
2000). 
Protein kinase A, B, and C (PKA, PKB, and PKC, respectively) are three 
of the earliest kinases discovered with involvement in many signaling pathways 
(Newton, 2003).  Each has a common conserved kinase core and a regulatory 
domain.  The regulatory domain is where the kinase is regulated by 
phosphorylation and dephosphorylation but also helps target the kinase to the 
appropriate cellular location (Newton, 2003).  PKB is of interest in this study as it 
is directly involved in cell survival.   
PKB, plays a critical role in controlling the balance between survival and 
apoptosis (Yoeli-Lerner and Toker, 2006).  There are 3 known isoforms which 
are generally considered to have the same function (Toker and Yoeli-Lerner, 
2006).  PKB promotes cell survival by inhibiting apoptosis through its ability to 
inactivate by phosphorylation several targets involved in apoptosis.  Prolonged 
survivability is the direct result of constitutive over phosphorylation of PKB in 
numerous cancers (Yoeli-Lerner and Toker, 2006).  Elevation in PKB-
phosphorylation makes the cell more resistant to apoptosis while declines in 
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PKB-phosphorylation make the cell more susceptible to apoptosis (Jeong et al., 
2007).  One hypothesis is that PKB is constitutively phosphorylated in carcinoma 
cells promoting survivability and that infection with BTV triggers an independent 
apoptotic mechanism which causes a reduction in PKB phosphorylation, thereby 
allowing the immortalized cell to enter apoptosis. 
 Besides suppressing PKB phosphorylation, BTV is also hypothesized to 
be activating pro-apoptotic processes.  One of the major pro-apoptotic signaling 
pathways associated with infection is the p38 mitogen-activated protein kinase 
(p38 MAPK) pathway (Porras et al., 2004).  P38 MAPK is also a known 
oncogene as aberrant MAPK phosphorylation can lead to prolonged survivability 
(Huynh et al., 2003).   
MAPKs include more than p38 MAPK.  Other MAPKs influence cell 
growth, differentiation, apoptosis, as well as cellular responses to stress 
(Ashwell, 2006).  Mutations in each member of the MAPK family can cause 
cancer.  In addition, because of their involvement in the inflammation and cell 
cycle regulation, each member could also be involved in BTV-induced cell death 
and cytokine expression (Hersey et al., 2006). 
 In general, MAPKs are a set of serine/threonine kinases which are 
evolutionarily conserved (Widmann et al., 1999).  The MAPK subfamily is 
activated by dual phosphorylation at a domain composed of a tyrosine two amino 
acids downstream of threonine in the TXXY motif (Ashwell, 2006).  MAPKs are 
inactive in their unphosphorylated state and become active when phosphorylated 
by MAPK kinases (MKKs).  MKKs are in turn phosphorylated by MAPK kinase 
  29 
 
kinases (MKKKs) (Dodeller and Schulze-Koops, 2006).  As a minimum, MAPKs 
require three sequential phosphorylations in order to be activated (Ray and 
Sturgill, 1988).  Once active, each member has a specific effector that it in turn 
activates by phosphorylation (Raman et al., 2007). 
The MAPKs include three subfamilies:  Extracellular signal-regulated 
kinases ERK1 and ERK2, Src associated protein kinases (SAPK) also known as 
c-Jun NH2-terminal kinases (SAPK-JNK1, -2, and -3), and the four p38 MAPK 
enzymes p38α, β, γ, δ (Johnson and Lapadat, 2002).  A fourth MAPK, ERK5, has 
also been identified though little is presently known about it (Zhou et al., 1995). 
The MAPK subfamilies each have specific functions.  ERK1 and ERK2 are 
involved in the regulation of mitosis and meiosis (Lloyd, 2006; Meloche and 
Pouysségur, 2007).  They can be activated by stimuli including growth factors, 
cytokines, virus infection, transforming agents and carcinogens (Wang, 2007; 
Valerie et al., 2007).  The ERK-1/2 path can also be activated by the proto-
oncogene RAS (Dance et al., 2008).  Mutated RAS persistently activates ERK-
1/2 which has been known to contribute to the increased proliferation rate of 
tumor cells (Ruscica et al., 2007).   
 The SAPK-JNK subfamily members are stress-activated proteins often 
activated when protein synthesis has been inhibited (Kyriakis et al., 1995; Singh 
and Czaja, 2007).  SAPK-JNKs phosphorylate the c-Jun transcription factor, 
which is part of the AP-1 transcription complex involved in transcription 
regulation, including cytokine gene expression (Salh, 2007).  SAPK-JNK’s are 
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also important in controlling apoptosis (Tournier et al., 2000; Takeda et al., 
2007). 
The third subfamily includes the p38 MAPKs.  There are four known p38 
MAPK isoforms with similar function.  P38 MAPK was first discovered from its 
involvement in TNFα-induced inflammation (Grivennikov et al., 2006; Aggarwal et 
al., 2006).  P38 MAPK is also involved in the expression of various other 
cytokines (Schindler et al., 2007; Patil and Kirkwood, 2007).  In addition to the 
usual pathway of activation, p38 MAPK can also be activated by the non-
enzymatic protein TAB1 (Ge et al., 2002), suggesting that there are multiple 
mechanisms of p38 MAPK regulation. 
P38 MAPK is also known to be associated with innate defense against 
dsRNA (Williams, 1999; Williams, 2001; Servant et al., 2002) and is a strong 
promoter of inflammation upon microbial challenge (O’Neill, 2006).  Viral-induced 
p38 MAPK activation generally leads to cell death as well as elevated cytokine 
production.  Chiang et al. (2006) observed p38 MAPK phosphorylation in BTV 
challenged primary lung microvascular endothelial cells.  They also found this 
activation could be reproduced using synthetic dsRNA.  In their studies, dsRNA-
induced the expression of the cytokines IL-1β, IL-6, and TNFα, consistent with 
p38 MAPK phosphorylation via innate immunity. 
 
OBJECTIVES AND HYPOTHESIS 
 
BTV preferentially replicates in transformed human cells relative to 
primary cells.  Understanding this selective trophism may lead to future 
treatments for cancer.  Our objectives were to determine how BTV replication in 
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carcinoma transformed human cells differs from replication in traditional host 
cells and how the human cells respond to BTV infection, including induction of 
apoptosis, changes in cytokine expression, and changes in intracellular signaling.  
Our hypothesis was that cell death and cytokine expression were directly related 
to viral replication and were the result of innate immune responses to BTV 
genomic dsRNA.  
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CHAPTER 2 
BLUETONGUE VIRUS (BTV)-INDUCED CELL DEATH CORRELATES 
DIRECTLY WITH BTV-INDUCED CYTOKINE EXPRESSION 
 
ABSTRACT 
 
Bluetongue virus (BTV) naturally infects ruminants, even though it is most 
commonly cultured in vitro in baby hamster kidney (BHK-21) and monkey kidney 
(Vero) cells.  BTV does not normally replicate in human cells though BTV 
administration has been shown to cause cell death and apoptosis in human HEP-
3G and A549 carcinoma transformed cell.  In addition, studies suggest that BTV 
infection of human cell lines is selective for transformed cells.  As a novel 
oncolytic virus, understanding the mechanism of cell death may lead to future 
therapies for cancer.  To better understand the mechanism of BTV-induced cell 
death, we determined the rate of BTV-induced as well as polyinosinic-
polycytidylic acid (poly I:C)-induced cell death in four cell lines (A498, HEP-G2, 
A549, and Vero).  We also determined the profile and magnitude of BTV-induced 
and poly-I:C-induced cytokine expression in each cell line.  Each cell line was 
found to express interleukin-6 (IL-6), IL-8, monocyte chemotactic protein 1 (MCP-
1), regulated upon activation T-cell expressed and secreted protein (RANTES), 
tissue inhibitor of metaloproteinases 1 (TIMP-1), and vasoendothelial growth 
factor (VEGF). IL-6, IL-8, MCP-1, and RANTES were found to be inducible both 
by BTV and poly I:C.  The magnitude of cytokine expression was cell line 
dependent.  BTV-induced cytokine expression correlated directly with BTV-
induced cell death. 
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INTRODUCTION 
 
The ability of bluetongue virus (BTV) to cause disease is heavily species 
dependent.  In cell culture, BTV’s ability to replicate and cause cell death is also 
quite variable.  BTV causes cell death in some human carcinoma transformed 
lines while primary cultures are not susceptible to BTV-induced cell death (Xiao 
et al., 2004; Chiang et al., 2006).  The ability of BTV to cause death in carcinoma 
transformed lines can be due to multiple mechanisms including innate immunity.  
Our objective was to determine the rates of cell death in 4 cell lines (A498, HEP-
G2, A549, and Vero). We also determined which cytokines are expressed upon 
infection and the contribution of dsRNA to this cytokine expression.   
Bluetongue virus (BTV), classified in the genus Orbivirus within the family 
Reoviridae, can cause disease in a variety of animals though only in ruminant 
species.  Though BTV naturally infects ruminants, it is most commonly cultured in 
vitro in baby hamster kidney (BHK-21) or monkey kidney (Vero) cells. BTV does 
not naturally replicate in humans, but can infect human cells in vitro.   Chiang et 
al. (2006) demonstrated viral S3 gene replication in BTV-serotype-10-treated 
human microvascular lung endothelial cells (ECs), and other studies have 
demonstrated BTV infectivity in transformed human cells (Xiao et al., 2004; Hu et 
al., 2008).  Fig. 2-1 and 2-2 show evidence of BTV-induced cell death in 
carcinoma transformed HEP-3G and A549 cells. 
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FIG. 2-1. Mock-
infected (left) and 
BTV-infected (right) 
HEP-3G cells.  
Visualized by light 
microscopy 36 hours 
P.I. by Hu et al., 
2008. 
 
FIG. 2-2. Mock-
infected (left) and 
BTV-infected (right) 
A549 cells.  
Visualized by light 
microscopy 36 hours 
P.I. by Hu et al., 
2008. 
 
Chiang et al. (2006) also observed elevated expression of TNFα, IL-1β, 
and IL-6 mRNA, in human microvascular lung ECs consistent with cytokine 
mRNA expression observed in bovine primary lung microvascular ECs (DeMaula 
et al., 2002). However, comparable cytokine expression could be induced with 
poly(inosinic):poly(cytidylic) acid (poly I:C), indicating BTV genomic dsRNA may 
be the cause of inducible cytokine expression (Chiang et al., 2006).  
Our objective was to characterize cell death as well as cytokine and 
chemokine expression, in BTV-serotype-17-infected human cells transformed by 
carcinoma (A498, HEP-G2, and A549 cells) and determine if poly I:C could 
induce similar changes.  We hypothesized that BTV would induce cell death in all 
tested cells in a time-dependent manner and that infection would lead to the 
production of pro-inflammatory cytokines.   
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MATERIALS AND METHODS 
 
Cell Culture 
Five cell lines were used in this study, including BHK-21 baby hamster 
kidney cells, A498 human kidney cells, HEP-G2 human liver cells, A549 human 
lung epithelial cells, and Vero African green monkey kidney cells (American Type 
Culture Collection, Manassas, VA).  Designated CCL-10, HTB-4, HB-8065, CCL-
185, and CRL-1587, respectively by the American Type Culture Collection. Each 
cell line was propagated in 75 cm2 flasks seeded at 1X106 cells and cultured in 
MEM/EBSS plus 10% FBS (Hyclone, Logan, UT) under a 5% CO2 atmosphere.  
 
BTV Stock Propagation 
Original stocks were triple plaque purified and stored frozen in aliquots 
(Kowalik et al., 1990; Li and Yang, 1990). Seed virus was prepared by infecting 
BHK-21 cells with frozen viral stock. Cells were infected at 80% confluency and 
harvested by scraping three days post infection (P.I.). After scraping, cells were 
pelleted, washed, resuspended in fresh media, then gently sonicated three times 
using a VirSonic 50 sonicator (VirTis Inc., Gardiner, NY) prior to 0.22 μm filter 
sterilization. Viral titer was determined by plaque assay, using Vero cell 
monolayers (Fillmore et al., 2002; Hayama and Li, 1994). Mock infections were 
similarly prepared using uninfected BHK-21 cells. 
 
Plate Preparation and BTV Infection 
96-well plates were seeded one day prior to experimentation in 
MEM/EBSS plus 10% FBS (Hyclone Laboratories, Logan, UT), such that the 
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culture was approximately 50% confluent when starting the experiment. Prior to 
experimentation, plates were rinsed with MEM/EBSS. BTV infection occurred at 
an MOI of 1 using BTV serotype 17. Mock infections were performed using a 
comparable volume of uninfected BHK-21 cells, prepared as described above. 
Plates were incubated at 37 °C under 5% CO2 in MEM/EBSS plus 5% FBS. 
 
Poly I:C Treatment of Cell Lines 
Stock poly I:C (Sigma, St. Louis, MO) was prepared at 2 mg/mL in 
MEM/EBSS and further prepared as serial half-log dilutions at 0, 0.1, 0.32, 1.0, 
3.2, 10, 32, and 100 μg/mL. Three 96-well plates per cell line were prepared as 
described above and treated with poly I:C (n=4). Samples of the cell culture 
supernatant were taken daily for 3 days (stored at -80 °C) for cytokine analysis, 
and one plate from each cell line was stained on days 1, 2, and 3 with neutral 
red.  
 
Neutral Red Staining 
A 0.034% solution of neutral red (Fisher Scientific, Fairlawn, NJ) in saline 
was prepared and filter sterilized. Immediately before use, the solution was 
diluted to 0.011% in MEM/EBSS. All media were removed from the plate, 200    
μL of the 0.011% neutral red solution was added, and plates were incubated at 
37 °C under 5% CO2 for two hours. Plates were then rinsed once with PBS, and 
neutral red was extracted by adding 100 μg/mL extraction buffer, made by 
combining 500 mL Sorensen citrate (0.1 M sodium citrate [Sigma, St. Louis, MO] 
and 0.1 M hydrochloric acid [Fisher Scientific, Fairlawn, NJ]) and 500 mL ethanol 
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(Pharmco-AAPER, Brookfield, CT). Absorbance at 540 nm was read using a 
SpectraMax Plus384 microplate reader (Molecular Devices, Sunnydale, CA). 
 
Quantitation of Secreted Analyte Expression 
Supernatant samples, collected previously and stored at -80 °C, were 
thawed at room temperature. Cytokines were detected by multiplex 
immunoassay (Quansys Biosciences, Logan, UT). Samples were tested for: 
Interleukin 1 alpha (IL-1α), IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-
13, interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), TNFβ, 
transforming growth factor beta 1 (TGF-β1), monocyte chemotactic protein 1 
(MCP-1), regulated upon activation T-cell expressed and secreted protein 
(RANTES), angiotensin 2 (ANG2), hepatocyte growth factor (HGF), tissue 
inhibitor of metalloproteinases (TIMP), thrombopoetin (TPO), vasoendothelial 
growth factor (VEGF), platelet derived growth factor (PDGF), eotaxin (EO), 
macrophage inflammatory protein 1 alpha (MIP-1α), and C-reactive protein 
(CRP). Follow-up experimentation was performed only on IL-1α, IL-1β, IL-6, IL-8, 
IFNγ, TNFα, MCP-1, and RANTES. The chemiluminescent signal was detected 
using an Alpha Innotech 8900 Gel Documentation System (San Leandro, CA). 
Plates were exposed for one minute, and signal intensity was quantified using 
software provided by Alpha Innotech. 
 
Statistical Analysis 
P-values were calculated in Excel (Microsoft Corporation, Redmond, WA) 
using a two-tailed Student’s t-test. 
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RESULTS 
 
Human Tumor Cells Detach and Die 
Progressively Throughout BTV Infection 
 
Numerous viruses are oncolytic (Vidal et al., 2006), including BTV (Hu et 
al., 2008).  In this study, we first explored cell death in three human cell lines 
transformed by carcinoma: A498, HEP-G2, and A549 to confirm the findings of 
Hu et al. (2008) and compare the effects of BTV in different types of tissue.  Cell 
death continuously increased over the course of infection for all tested cells lines.  
The A498 cells were most susceptible to BTV-induced cell death, with only 12% 
viability on day 3, compared with mock-infected cells, followed by Vero cells with 
43% viability on day 3.  A549 cells were comparable to Vero cells with 45% 
viability on day 3 followed last by HEP-G2 cells with 70% viability on day 3.   
Surprisingly, BTV caused greater cell death in A498 cells than in the common 
laboratory host, Vero.  Percent viability on day 3 in each cell line is shown in Fig. 
2-3.  Viability in each cell line was also determined when treated with poly I:C 
instead of BTV.  Cells were treated at either 1 μg/mL or 50 μg/mL.  One μg/mL 
poly I:C did not cause a statistically significant change in viability in any tested 
cell line.  Fifty μg/mL poly I:C caused statistically significant cell death only in 
A498 cells, with death comparable to BTV-induced cell death (see Fig. 2-3).   
 
Inflammatory Mediators Are Elevated  
During BTV Infection 
 
Samples from the viability study were tested for 25 different cytokines and 
chemokines.  Six were found to be expressed by these three cell lines. 
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FIGURE 2-3:  Percent viability of A498, HEP-G2, A549, and Vero cells. 
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FIG. 2-3.  Percent viability of A498, HEP-G2, A549, and Vero cells as 
determined by neutral red staining 3 days P.I.  Cells were either mock-
infected, BTV-infected at an MOI of 1, 1 μg/mL poly I:C treated, or 50 
μg/mL poly I:C treated (n=4).  * indicates conditions with statistically 
significant decreases in cell viability compared with the placebo.  
Of the six, four (IL-6, IL-8, MCP-1 and RANTES) were found to be significantly 
elevated upon BTV infection, while the other two (VEGF and TIMP) were 
constitutively expressed by the cell but did not change significantly with infection 
(data not shown). 
A new array with IL-6, IL-8, MCP-1, RANTES, IL-1α, TNFα, IL-10, IL-
12p70, MIP-1α, and EO was prepared to further explore cytokine expression.  
Using this array, IL-6, IL-8, MCP-1, and RANTES were found expressed from all 
4 cell lines with cytokine expression correlating directly with cell death.  
Concentrations of the four BTV-induced cytokines are shown in table 2-1.  Also 
shown in table 2-1 are cytokine levels from cells treated with poly I:C at 1 μg/mL 
and 50 μg/mL.  A498, A549, and Vero cells expressed cytokines in response to  
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TABLE 2-1 
 
Cytokine Expression (pg/mL) from A498, A549 and Vero Cells 
Seeded in 96-well Plates 3 Days Post Treatment (n=4) 
 
  A498  A549  Vero 
  pg/mL STDEV  pg/mL STDEV  pg/mL STDEV 
Mock-
infected IL-6 280 90 200 40  1010 140
 IL-8 1100 250 630 60  0 0
 MCP-1 4650 620 1110 80  2520 300
 RANTES 150 50 190 20  0 0
    
BTV-
infected IL-6 3310 310 540 100  12700 1720
 IL-8 1810 250 3100 300  2770 570
 MCP-1 8450 1230 2950 300  19900 1780
 RANTES 390 120 5670 290  200 60
    
Poly I:C  IL-6 3850 1180 390 170  2691 820
1.0  μg/mL IL-8 8900 890 1060 90  30 10
 MCP-1 14900 530 1720 300  8730 1770
 RANTES 3820 1060 1130 100  610 100
    
Poly I:C  IL-6 13600 740 420 70  14800 2070
50  μg/mL IL-8 13300 470 4590 380  310 100
 MCP-1 18900 770 7080 810  20800 730
 RANTES 7580 1480 6050 900  2290 890
poly I:C treatment while HEP-G2 cells did not express. 
Prior studies by Chiang et al. (2006) showed that IL-1β and TNFα were 
secreted from BTV infected human lung primary ECs, but neither one was 
expressed during this study.  It is possible that IL-1β and TNFα are responses 
specific to human primary lung microvascular ECs, MALT-associated lymphocyte 
carryover in the primary cell isolation process, or that the pathway is inactivated 
as a result of  transformation by carcinoma.  
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Poly I:C Causes Cell Death in A498 Cells,  
but Induces Cytokine Expression in A498,  
A549, and Vero Cells 
 
One of the possible mechanisms by which BTV could cause cytokine 
expression is through innate immunity.  Chiang et al. (2006) used BTV-10 as a 
model for virus-induced vascular permeability in human ECs and found that the 
effects BTV had on the ECs could be replicated using synthetic dsRNA.  To test 
for innate immunity’s role in the host cell response to BTV, each cell line was 
then treated with poly I:C in a dose dependent manner, ranging from 0.1 μg/mL 
to 100 μg/mL.  Percent viability as a function of poly I:C concentration is shown in 
Fig. 2-4.  This study demonstrated no statistically significant change in cell  
viability in HEP-G2, A549, or Vero cells treated with poly I:C, but a strong change  
was dose dependent between 1 and 100 μg/mL but displayed a second peak in 
cell death at 0.32 μg/mL. 
Poly I:C treated samples were sampled at 24, 48, and 72 hours post 
treatment and assayed for cytokine expression.  A498, A549, and Vero cells all 
expressed cytokines during poly I:C treatment while HEP-G2 cells did not.  Both 
A498 and Vero cells had peak cytokine responses at 0.32 μg/mL and 100 μg/mL 
poly I:C, while A549 cells only showed poly-I:C-induced cytokine expression at 
concentrations above 3.2 μg/mL.  Cytokine expression did increase slightly in 
A549 cells treated with 0.32 μg/mL, suggesting there may have been a second 
peak, though the change was not statistically significant.  Interestingly, cytokine 
expression stopped or slowed dramatically 48 hours post treatment, also in a cell 
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line dependent manner.  Fig. 2-5 through 2-16 show cytokine expression from 
A498, A549, and Vero cells as a function of poly I:C concentration and time. 
 
DISCUSSION 
 
Bluetongue disease was first characterized over 100 years ago in BTV’s 
natural host ruminants.  It has only recently been shown to have selectively 
oncolytic effects in certain human cell lines (Xiao et al., 2004; Hu et al., 2008).  
Selective oncolysis by viruses has been observed previously in both DNA and 
RNA viruses, each employing different mechanisms (Strong et al., 1998; 
Vorburger et al., 2004; Vidal et al., 2006).  Little is known about the mechanism 
by which BTV causes oncolysis.  BTV is closely related to reovirus, another 
FIG. 2-4 Percent viability as a function of poly I:C concentration. 
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FIG. 2-4.  Percent viability as a function of poly I:C concentration.  
A498, HEP-G2, A549, and Vero cells were treated with 
concentrations of poly I:C ranging from 0.1 to 100 μg/mL (n=4) and 
stained with neutral red three days P.I.  A498 cell viability was 
significantly affected by treatment with poly I:C. 
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FIGURE 2-5 IL-6 expression in A498 cells as function poly I:C concentration
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FIG. 2-5.  IL-6 expression in A498 cells as a function of poly I:C 
concentration, at 24, 48, and 72 hours P.I.  Cells were treated with 
concentrations of poly I:C ranging from 0.1 to 100 μg/mL (n=4) 
and assayed for cytokine expression using supplies from Quansys 
Biosciences. 
 
 
FIGURE 2-6 IL-8 expression in A498 cells as function poly I:C concentration
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FIG. 2-6.  IL-8 expression from A498 cells as a function of poly I:C 
concentration at 24, 48, and 72 hours P.I.  Cells were treated with 
concentrations of poly I:C ranging from 0.1 to 100 μg/mL (n=4) 
and assayed for cytokine expression using supplies from Quansys 
Biosciences. 
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FIGURE 2-7 MCP-1 expression in A498 cells as function poly I:C concentration
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FIGURE 2-8 RANTES expression in A498 cells as function poly I:C concentration
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FIG. 2-7.  MCP-1 expression from A498 cells as a function of 
poly I:C concentration at 24, 48, and 72 hours P.I.  Cells were 
treated with concentrations of poly I:C ranging from 0.1 to 100 
μg/mL (n=4) and assayed for cytokine expression using supplies 
FIG. 2-8.  RANTES expression from A498 cells as a function of 
poly I:C concentation at 24, 48, and 72 hours P.I.  Cells were 
treated with concentrations of poly I:C ranging from 0.1 to 100 
μg/mL (n=4) and assayed for cytokine expression using supplies 
from Quansys Biosciences. 
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FIGURE 2-9 IL-6 expression in A549 cells as function poly I:C concentration
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FIGURE 2-10 IL-8 expression in A549 cells as function poly I:C concentration
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FIG. 2-9.  IL-6 expression from A549 cells as a function of poly 
I:C concentration at 24, 48, and 72 hours P.I.  Cells were 
treated with concentrations of poly I:C ranging from 0.1 to 100 
μg/mL (n=4) and assayed for cytokine expression using 
supplies from Quansys Biosciences. 
FIG. 2-10.  IL-8 expression from A549 cells as a function of poly 
I:C concentration at 24, 48, and 72 hours P.I.  Cells were treated 
with concentrations of poly I:C ranging from 0.1 to 100 μg/mL 
(n=4) and assayed for cytokine expression using supplies from 
Quansys Biosciences. 
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FIGURE 2-11 MCP-1 expression in A549 cells as function poly I:C concentration
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FIGURE 2-12 RANTES expression in A549 cells as function poly I:C concentration
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FIG. 2-11.  MCP-1 expression from A549 cells as a function 
of poly I:C concentration at 24, 48, and 72 hours P.I.  Cells 
were treated with concentrations of poly I:C ranging from 0.1 
to 100 μg/mL (n=4) and assayed for cytokine expression 
using supplies from Quansys Biosciences. 
FIG. 2-12.  RANTES expression from A549 cells as a function 
of poly I:C concentration at 24, 48, and 72 hours P.I.  Cells 
were treated with concentrations of poly I:C ranging from 0.1 to 
100 μg/mL (n=4) and assayed for cytokine expression using 
supplies from Quansys Biosciences. 
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FIGURE 2-13 IL-6 expression in Vero cells as function poly I:C concentration
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FIGURE 2-14 IL-8 expression in Vero cells as function poly I:C concentration
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FIG. 2-13.  IL-6 expression from Vero cells as a function of poly 
I:C concentration at 24, 48, and 72 hours P.I.  Cells were treated 
with concentrations of poly I:C ranging from 0.1 to 100 μg/mL 
(n=4) and assayed for cytokine expression using supplies from 
Quansys Biosciences. 
FIG. 2-14.  IL-8 expression from Vero cells as a function of poly 
I:C concentration at 24, 48, and 72 hours P.I.  Cells were treated 
with concentrations of poly I:C ranging from 0.1 to 100 μg/mL 
(n=4) and assayed for cytokine expression using supplies from 
Quansys Biosciences. 
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FIGURE 2-15 MCP-1 expression in Vero cells as function poly I:C concentration
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FIGURE 2-16 RANTES expression in Vero cells as function poly I:C concentration
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FIG. 2-15.  MCP-1 expression from Vero cells as a function of 
poly I:C concentration at 24, 48, and 72 hours P.I.  Cells were 
treated with concentrations of poly I:C ranging from 0.1 to 100 
μg/mL (n=4) and assayed for cytokine expression using supplies 
from Quansys Biosciences. 
FIG. 2-16.  RANTES expression from Vero cells as a function of 
poly I:C concentration at 24, 48, and 72 hours P.I.  Cells were 
treated with concentrations of poly I:C ranging from 0.1 to 100 
μg/mL (n=4) and assayed for cytokine expression using supplies 
from Quansys Biosciences. 
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oncolytic virus, and may share a similar mechanism, though BTV is predicted to 
have particular advantages over reovirus because humans are seronegative to 
BTV (Wildner, 2003). 
To further explore the therapeutic potential of BTV in cancer, we 
compared cell death and cytokine expression in A498, HEP-G2, and A549 cells 
during BTV infection and poly I:C treatment.  Our hypothesis was that BTV 
infection causes cell line dependent death while simultaneously inducing cytokine 
expression.  We showed elevated expression of pro-inflammatory cytokines from 
BTV-17 infected human carcinoma transformed cells (see Table 2-1) and that 
infected cells die as a direct result of infection (see Fig. 2-1).  Cytokine 
expression and cell death directly correlated between cell lines and with time.  
The rate of cytokine expression and cell death were primarily cell line dependent, 
but continuously increased as long as there were viable cells, indicating that 
activation was continuous until death.  All tested cell lines expressed the same 
cytokines, suggesting the mechanism of induction is similar in each cell line.  We 
hypothesized that cell death and cytokine expression are related through 
conserved intracellular signaling events.  Various intracellular pathways were 
tested for involvement and are discussed in Chapter 4.   
We also hypothesized that innate immunity was the initiator of this 
intracellular signaling.  Prior studies from our lab infecting A498, HEP-G2, and 
A549 cells with DNA and RNA viruses showed that all three cell lines responded 
to viral infection with the expression of IL-6, however, only cells infected with 
RNA viruses induced RANTES expression (data not shown).  In this experiment, 
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RANTES was observed in all tested lines suggesting each cell line recognized 
the virus as an RNA virus and responded accordingly.  Because every cell line 
responded with RANTES expression, we conclude that the event is conserved 
across each cell line and is functional in each cell line.  The cytokine expression 
pattern is consistent with type-I interferon signaling through the transcription 
factors IRF3 and IRF7 leading to JAK-STAT signaling which generally results in 
the production of CXC chemokine ligand 10 (CXCL10), MCP-1, and RANTES.  
TLR3 is also known to activate the type-I interferon pathway as well as the 
nuclear translocation factor kappa B (NFκB) pathway, though the cytokine 
pattern is not fully consistent with this.  We observe IL-6 and IL-8 expression, but 
not IL-1 or TNFα as is generally observed in NFκB associated signaling.  The 
lack of IL-1 or TNFα may be carcinoma or cell type related. 
Though there are multiple innate immunity mechanisms, focus was on 
immunity to dsRNA, since BTV’s genome is dsRNA.  To test the contribution of 
dsRNA to the observed cell death and cytokine expression, cells were treated 
with poly I:C.  First, cells were treated with either 1 μg/mL or 50 μg/mL poly I:C.  
Treatment resulted in cell death only in A498 cells, and only at 50 μg/mL (Fig. 2-
1), suggesting that BTV-induced cell death was not entirely the result of an innate 
immune response to BTV dsRNA; also evidenced by no concentration of poly I:C 
generating statistically significant changes in viability in HEP-G2, A549, or Vero 
cells. 
A498 cells have a greater sensitivity to dsRNA than the other cell lines, 
which may explain why these cells are more susceptible to BTV-induced cell 
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death but does not entirely explain BTV’s mechanism of inducing cell death.  The 
experiment was repeated using a broader range of poly I:C concentrations (Fig. 
2-2).  Like the previous study, only the A498 cells died in response to poly I:C 
treatment, but the study revealed two peaks in poly-I:C-induced cell death.  One 
peak at 0.32 μg/mL and a second peak at 100 μg/mL This type of curve 
suggested two different dsRNA response mechanisms.  One functional only at 
low concentrations of poly I:C, and the other responding only at very high 
concentrations of poly I:C.  When tested for cytokines, the same trend was 
observed in the A498 cells (Fig. 2-3 through 2-6).  The similar patterns suggest 
that the same two mechanisms which induced cell death in A498 cells also 
induced cytokine expression.  HEP-G2, A549, and Vero cells were also tested for 
cytokines.  HEP-G2 cells did not express any cytokines in response to poly I:C, 
A549 cells expressed cytokines in a dose dependent manner mainly at 
concentrations greater 3.2 μg/mL, and Vero cells displayed a cytokine pattern 
similar to A498 cells.  Vero cells having a pattern similar to A498 cells is not 
entirely surprising given that both cell lines were originally isolated from kidneys, 
suggesting the second mechanism may be more active in kidney derived cells.  
There remains, however, distinctions between A498 and Vero cells, including a 
lack of poly-I:C-induced cell death in Vero cells.  Even though both anti-dsRNA 
mechanisms in Vero cells are recognizing the poly I:C, the response does not 
lead to  apoptosis in Vero cells.   
We conclude from these experiments, that BTV induces cytokine 
expression in immortalized human A498, A549, and HEP-G2 cells and 
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subsequently kills the infected cell with cell line dependent severity.  The BTV-
induced cytokine response is pro-inflammatory, including IL-6, IL-8, MCP-1, and 
RANTES.  Double-stranded RNA can induce expression of the same cytokines 
but only causes cell death in A498 cells, and only at unnaturally high 
concentrations.  We conclude that BTV-induced cell death is not the result of 
innate immune responses to BTV dsRNA, though observed cytokines can be 
partially attributed to innate immune responses to dsRNA. 
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CHAPTER 3 
 
BLUETONGUE VIRUS INDUCED CELL DEATH AND CYTOKINE 
EXPRESSION IS CAUSED BY THE CELL’S  
RESPONSE TO INFECTION 
 
ABSTRACT 
 
 Bluetongue virus (BTV) is a dsRNA virus which must utilize its own 
replication machinery for transcription but must rely on host machinery for 
translation.  Packaging of viral transcription proteins makes BTV less reliant on 
host mechanisms than other viruses, which may contribute to its diverse species 
tropism in vitro.  Though BTV does not naturally cause disease in humans, it can 
cause cell death and cytokine expression in human carcinoma transformed cells.  
To better understand the mechanism of induced cell death, viral RNA and protein 
expression were quantified by qRT-PCR and Western blotting, respectively.  Our 
hypothesis was that cell death and cytokine expression are a direct result of viral 
replication and thus RNA and protein expression would directly correlate with cell 
death and cytokine expression.  BTV RNA and protein were found in all tested 
human carcinoma transformed cell lines, but RNA expression showed no 
correlation with cell death or cytokine expression while protein expression 
inversely correlated with cell death and cytokine expression.  The data indicates 
that cell death and cytokine expression are not a direct result of the virus, but the 
result of the cell’s response to infection. 
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INTRODUCTION 
 
 Bluetongue virus (BTV) is a dsRNA virus with a genome composed of 10 
segments (Verwoerd, 1970).  Each segment codes for a different protein except 
segment 10 which codes for two proteins (NS3 and NS3a) via a non-overlapping 
open reading frame (Mertens and Sangar, 1985).  During replication, proteins 
necessary in mRNA processing are usually produced first, followed by structural 
proteins and progeny genomic RNA (Roy, 1989).  Prior to this study, BTV RNA 
expression of all ten genes in human cells had not been tested. 
Protein expression was also compared between human cell lines.  Viral 
proteins are classified into two general types: structural and non-structural.  The 
latter type includes all proteins not normally found within the viral protein itself, 
but are synthesized during replication for the purpose of facilitating replication. 
The objective of this study was to characterize viral RNA and protein 
expression in infected human cell lines and compare these results with the cell 
death and cytokine expression observed in Chapter 2.  The hypothesis was that 
RNA expression and protein expression directly correlate between the tested 
human cell lines, and that cell death increases proportionately with accumulation 
of viral RNA and protein.   
 
MATERIALS AND METHODS 
 
Cell Culture 
Five cell lines were used in this study, including BHK-21 baby hamster 
kidney cells, A498 human kidney cells, HEP-G2 human liver cells, A549 human 
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lung epithelial cells, and Vero African green monkey kidney cells (American Type 
Culture Collection, Manassas, VA).  Designated CCL-10, HTB-4, HB-8065, CCL-
185, and CRL-1587, respectively by the American Type Culture Collection. Each 
cell line was propagated in 75 cm2 flasks seeded at 1X106 cells and cultured in 
MEM/EBSS plus 10% FBS (Hyclone, Logan, UT) under a 5% CO2 atmosphere.  
 
BTV Stock Propagation 
Original stocks were triple plaque purified and stored frozen in aliquots 
(Kowalik et al., 1990; Li and Yang, 1990). Seed virus was prepared by infecting 
BHK-21 cells with frozen viral stock. Cells were infected at 80% confluency and 
harvested by scraping three days post infection (P.I.). After scraping, cells were 
pelleted, washed, resuspended in fresh media, then gently sonicated three times 
using a VirSonic 50 sonicator (VirTis Inc., Gardiner, NY) prior to 0.22 μm filter 
sterilization. Viral titer was determined by plaque assay, using Vero cell 
monolayers (Hayama and Li, 1994; Fillmore et al., 2002). Mock infections were 
similarly prepared using uninfected BHK-21 cells. 
 
BTV mRNA Expression 
BHK-21, A498, HEP-G2, and A549 cells were seeded into separate 6-well 
plates at 1 X 105 cells per well.  Three wells from each cell line were infected with 
BTV serotype 17 at an MOI of 1, while the other three wells were mock infected.  
At 24, 48, and 72 hours, cells from one BTV infected well and one mock infected 
well were collected by scraping. Collected samples were centrifuged, washed 
once with PBS, and stored at -80C until all samples had been collected.  Total 
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RNA was isolated from each sample using the Qiagen total RNA extraction kit 
(Valencia, CA) and reverse transcribed using the Bio-Rad reverse transcription 
kit and random hexamer primers (Hercules, CA).  After reverse transcription, the 
presence and amount of each BTV gene was determined by quantitative real 
time PCR (qRT-PCR) as described by Buccambusco et al. (2005) using the 
primers listed in Table 3-1. 
 
TABLE 3-1 
Primer Sequences and Gene Location Used in the 
Quantitation of Each BTV cDNA by qRT-PCR 
 
                Primer          Location                       Sequence 
L1 F 2107-2126 5’-ACAAAGGATTCGACACGCTT-3’ 
   
L1 R 2402-2383 5’-TTCATGTCCACACTTCGCCA-3’ 
   
L2 F 1224-1347 5’-GACGACTTATGACAGCGGATACAT-3’ 
   
L2 R 1547-1526 5’-GCAAAACTAACTCGGACCGTAA-3’ 
   
L3 F 2209-2233 5’-TGTTAGAGGCCCCACCAGAAATAG-3’ 
   
L3 R 2424-2403 5’-CATAGCTGAAAGGTAAGCCCTG-3’ 
   
M1 F 1624-1643 5’-AAACGGCTGACGAACTGAAA-3’ 
   
M1 R 1848-1829 5’-CATTTCTCACATGCCATGGA-3’ 
   
M2 F 565-589 5’-AGGCTTCAGAGAGAAGTCAGGACG-3’ 
   
M2 R 774-751 5’-CGGTTGCTACAGCAGTGGCCATA-3’ 
   
M3 F 36-54  5’-TGGAGCGCTTTTTGAGAA-3’ 
   
M3 R 277-257 5’-GACTGTTTCCCGATCATACA-3’ 
   
S1 F 13-31  5’-AGCCATATGTTGAGTATA-3’ 
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S1 R 284-267 5’-TAGAGATGGACACTATCGC-3’ 
   
S2 F 1024-1043 5’-TGAGCGTGTTGCTTTTGTCT-3’ 
   
S2 R 1104-1086 5’-AATCATGCGGTCACAAGCG-3’ 
   
S3 F 16-36  5’-ATGTCAGCTGCGATGCTTCT-3’ 
   
S3 R 264-244 5’-TATGCGTCTATCCACATCTG-3’ 
   
S4 F 732-752 5’-CCAAGGTCCGTATCGTGTAGA-3’ 
   
S4 R 821-802 5’-TAAGTGTGTAGCGCCGCGTA-3’ 
 
 
BTV Protein Western Blot 
Cells were prepared as described by Li and Yang (1990).  Briefly, two 
flasks of cells from each cell line were seeded separately at 1 X 106 cells/flask 
and allowed to adhere overnight.  One flask from each cell line was infected with 
BTV serotype 17 at an MOI of 1, while the second flask was mock infected.  Cells 
were harvested 72 hours P.I. by scraping.  Samples were washed once in PBS 
and the cell pellet stored at -80 oC until use.  Prior to electrophoresis, cell pellets 
were resuspended in PBS and lysed by sonication.  The protein concentration of 
each sample was determined by BCA assay and each sample adjusted to 1 
mg/mL protein using PBS.  Samples were then diluted to a final concentration of 
500 μg/mL in Lameli buffer with 5% 2-ME and boiled for 10 minutes.  Boiled 
samples were electrophoresed on 10% polyacrylamide, and electrophoretically 
transferred to PVDF membrane (12V 1A 90 min).  Membranes were blocked with 
5% BSA for 30 minutes then incubated with rabbit anti-BTV17 antibody diluted 
1:1000 in 5% BSA overnight at 4 oC with gentle shaking.  Antibody binding was 
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detected by incubating the membrane with HRP-labeled goat anti-rabbit 
secondary antibody (Sigma, St. Louis, MO) diluted 1:5000 for 2 hours at room 
temperature with gentle shaking.  HRP activity was visualized with TMB 
membrane substrate (Sigma, St. Louis, MO). 
 
Statistical Analysis 
P-values were calculated in Excel (Microsoft Corporation, Redmond, WA) 
using two-tailed Student’s t-test.  Coefficient of variation (%CV) was calculated 
by dividing the standard deviation of the group by the group average. 
 
RESULTS 
 
All BTV Genes are Transcribed During Infection 
Data from Chapter 2 showed that cell death in human cells is cell line 
dependent.  To under stand how this cell death related to viral replication, RNA 
for each gene was quantified by qRT-PCR.  RNA for every BTV gene was found 
expressed in the tested human cell lines, consistent with active viral replication.  
The RT-PCR data shows that the detected viral RNA was not from the genome 
of the original infecting virus nor a cross reaction with cellular RNA.  Fig. Tables 
3-2 through 3-5 show the cycle threshold, c(T), values for each gene in BHK-21, 
A498, HEP-G2, and A549 cells 72 hours P.I.  Figures 3-1 to 3-11 show the qRT-
PCR amplification curves for each primer set. 
Cell lines showed strong consistency in amount of each gene produced, 
with cycle threshold [c(T)] values between genes in the same cell line  
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maintaining an average %CV of 7.7%.  In BHK-21, the average c(T) was 35.8 +/- 
4.3 in mock-infected and 14.9 +/- 1.4 in BTV-infected cells.  For A498, the 
average was 34.9 +/- 3.2 for mock-infected and 15.9 +/- 1.4 for BTV-infected 
cells.  Average HEP-G2 mock-infected cell c(T) was 32.6 +/-2.3 but 23.1 +/- 1.3 
in BTV-infected cells, while A549 mock-infected cells averaged 34.9 +/- 2.3 but 
29.9 +/- 2.2 in BTV-infected cells. 
 
TABLE 3-2 
 
BHK-21 Cycle Threshold Values at 72 Hours P.I. 
 
 Control Infection 
Gene c(T) Tm c(T) Tm 
L1 31.1 84 14.7 83 
L2 37.8 76 15.9 80 
L3 30.6 83 15.3 83 
M1 None NA 14.1 83 
M2 35.6 78 14.3 85 
M3 None NA 15.1 82 
S1 None NA 17.6 85 
S2 32.7 83 12.9 82 
S3 None NA 14.8 84 
S4 30.1 82 13.5 83 
GAPDH 19.5 85 23.3 85 
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TABLE 3-3 
 
A498 Cycle Threshold Values at 72 Hours P.I. 
 
 Control Infection 
Gene c(T) Tm c(T) Tm 
L1 37.0 83 15.7 83 
L2 38.6 75 17.5 80 
L3 32.9 83 16.2 83 
M1 31.7 81 15.1 83 
M2 33.1 85 15.2 85 
M3 None NA 14.6 83 
S1 33.7 74 18.8 84 
S2 30.4 84 14.8 82 
S3 33.7 82 16.2 84 
S4 37.8 82 14.7 84 
GAPDH 21.6 85 21.4 85 
 
 
 
TABLE 3-4 
 
HEP-G2 Cycle Threshold Values at 72 Hours P.I. 
 
 Control Infection 
Gene c(T) Tm c(T) Tm 
L1 33.3 83 22.6 83 
L2 37.8 77 24.7 80 
L3 30.6 82 23.0 83 
M1 30.3 75 22.5 82 
M2 32.6 83 23.3 85 
M3 None NA 22.7 82 
S1 33.4 74 25.4 85 
S2 32.0 82 21.0 82 
S3 31.3 84 22.7 84 
S4 31.6 82 22.5 83 
GAPDH 21.3 86 21.1 86 
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TABLE 3-5 
 
A549 Cycle Threshold Values at 72 Hours P.I. 
 
 Control Infection 
Gene c(T) Tm c(T) Tm 
L1 35.4 84 29.4 83 
L2 36.4 76 32.0 80 
L3 33.4 80 29.5 83 
M1 32.5 75 29.1 83 
M2 33.3 79 32.1 84 
M3 None NA 32.5 82 
S1 34.1 74 33.0 85 
S2 32.8 81 26.8 81 
S3 34.1 83 27.6 83 
S4 36.4 79 28.0 83 
GAPDH 19.7 86 19.8 86 
To ensure consistency in the data, RNA concentrations in the purified 
RNA samples were determined spectrophotometrically at A260 and A280 
absorbance and then adjusted to 50 μg/mL total RNA prior to reverse 
transcription.  Furthermore, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was measured simultaneously to confirm normalization of the samples.  
The average %CV of GAPDH c(T) values between mock-infected and BTV-
infected cells was 0.7%.  Average GAPDH values between cell lines was 21.0 +/- 
1.3 corresponding to a %CV of 6.1%, suggesting good consistency between 
samples.   
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BTV Proteins Are Expressed During Infection 
In order to identify viral protein expression, Western blots were performed 
on mock-infected and BTV-infected cultures.  Western blot results using purified 
rabbit anti-BTV17 antisera are shown in Fig. 3-12.  Bands were identified in all 3 
cell lines with molecular weights consistent with BTV proteins NS2 and VP7.  
Band intensity for the two putative BTV proteins was strongest in HEP-G2 cells, 
followed by A549 cells.  BTV protein expression was weakest in A498 cells, with 
only one viral protein band clearly detectable on the Western blot (see Fig. 3-12). 
 
 
FIG. 3-12.  Western blot 
of mock-infected and 
BTV-infected cells.  
A498, HEP-G2, and 
A549 cells were either 
infected with BTV 
serotype 17.  Cells  
were harvested 72 
hours P.I.  The  
samples were 
processed by sonication 
and  protein content 
adjusted to 500 mcg/mL 
prior to PAGE analysis.  
Gel was blotted to  a 
PVDF membrane and 
stained with rabbit anti-
BTV17 antisera, and 
visualized with TMB 
substrate. 
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DISCUSSION 
 
BTV has therapeutic potential in cancer because of its ability to kill human 
cancer cells and reduce human tumor size (Xiao et al., 2004).  In this experiment 
BTV is shown to replicate in each cell, though the efficiency of replication is 
heavily cell line dependent. 
RNA production was highest in the kidney derived A498 cells, followed by 
HEP-G2 and last by A549 cells.  RNA concentrations in A498 cells were 
comparable to RNA concentrations observed in the laboratory host BHK-21 
(Table 3-2).  It may be that the high viral RNA expression is related to the tissue 
type as BHK-21 and A498 are both kidney derived cells.  However, protein 
expression in A498 cells was severely limited in comparison to the other cell lines 
as determined by Western blotting with anti-BTV17 antisera.  Even though A498 
cells produced the most RNA of any cell, they produced the least protein.  HEP-
G2, on the other hand, showed strong RNA expression, though not nearly as 
high as A498 cells, but showed the most BTV protein (Fig. 3-12).  A549 cells 
expressed the least amount of BTV RNA, with concentrations barely above 
controls, though every BTV gene was detected in A549 cells.   
Within each cell line, all of the genes quantified in a narrow range of cycle 
threshold values (1.29-17.6 for BHK-21 cells, 14.6-18.8 for A498 cells, 21.0-25.4 
for HEP-G2 cells, and 26.8-33.0 for A549 cells).  This narrow range suggests 
there was no preferential over/under expression or over/under degradation of a 
particular gene.   
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Based on c(T) numbers, of the human cell lines, A498 cells produced the 
most viral RNA, with levels within the standard deviation of the BHK-21 cells.  
HEP-G2 produced the next highest level of viral RNA, though considerably less 
than A498.  Human A549 cells showed the lowest amount of RNA, with levels 
clearly above background, but substantially lower than HEP-G2 and A498 (see 
Table 3-1 through 3-4).  Testing was performed 72 hours P.I., so these values 
represent cumulative RNA expression over 3 days.   
One possibility for the differences in RNA levels is differences in the rate 
of RNA degradation in each cell line, though BTV viral RNA would be expected to 
degrade at a faster rate than cellular mRNA due to its lack of polyadenylation.  
However, the testing was a measure of total viral RNA, and genomic dsRNA is 
not degraded by the host and is therefore expected to accumulate as a function 
of time and replication rate.  Given the lack of a clear relationship between RNA 
and protein among the human cells, the differences in expression are probably 
not related to rates of RNA degradation but related to the replication rate being 
influenced by the intracellular environment.  Specifically, the activity of antiviral 
defense mechanisms, such as type I interferon. 
The role of the intracellular environment suggests that viral tropism may 
be as much related to innate immune system activity and usability of the host 
transcription/translation machinery as it is related to receptor expression.  BTV 
may equally infect various tissues, but only concentrate in the tissues in which it 
replicates most efficiently. 
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Hence, BTV may equally infect primary and cancerous cells, but only 
cancerous cells are conducive to efficient viral replication.  A strong possibility, 
since cancer cell expression is highly modified from its primary counterpart with 
various genes turned on and others, such as innate defense mechanisms, turned 
off. 
The influence of the intracellular environment is supported by the inverse 
correlation between protein expression and cell death/cytokine expression.  A498 
cells expressed the most RNA but least protein.  These cells also displayed the 
most cell death and cytokine expression.  HEP-G2 which expressed the most 
protein was the least susceptible to BTV-induced cell death, and expressed the 
least amount of cytokines.  A549 cells, which showed the least amount of RNA, 
showed modest protein expression, cell death, and cytokine expression. 
This inverse relationship between cell death/cytokine expression and viral 
protein expression indicates that the cell death and cytokine expression are both 
functions of the cell’s response to infection rather than a direct result of the virus.  
If the virus was completely in control, all four variables would be expected to rise 
proportionately.  As the virus replicates, RNA and protein expression would 
increase, and as replication completes, cell death would increase, and cytokine 
expression would increase steadily.  In this scenario, differences in fitness 
between cell lines would lead to proportionate changes in all four variables. 
However, expression between the four variables is not proportionate indicating 
influences by the host cell.   
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Possible influences include innate immunity, as well as altered signaling.  
For example, the type-I interferon response leads to cytokine expression, 
activation of the caspase pathways, and phosphorylation of EIF-2 thereby 
shutting down protein synthesis (Watanabe, 2004).  In the presence of a 
functioning type-I interferon pathway, viral protein production would remain low in 
the presence of high viral RNA and would be inversely related to cell death and 
cytokine expression, as was seen in A498 cells.  The same pattern, however was 
not seen in every cell line, suggesting there may be other mechanisms present 
as discussed in Chapter 4. 
In conclusion, the objective of this experiment was to correlate BTV RNA 
and protein expression to the cytokine and cell death data of the previous 
experiment.  Our hypothesis was that cell death and cytokine expression 
correlates directly with viral RNA and protein expression consistent with cytokine 
expression and cell death the direct result of viral replication.  We observed high 
levels of both RNA and protein in each cell line, showing that the virus is fully 
capable of infecting and replicating in each line; however, comparisons between 
the three human cell lines showed no obvious correlation between RNA and cell 
death or cytokine expression, and an inverse correlation between viral protein 
expression and cell death.  The data does not support our initial hypothesis, but 
rather suggests that the magnitude of cell death and cytokine expression is cell 
line dependent and a function of the cell’s ability to respond to infection.   
No matter the reason for BTV’s selective infectivity, it is clear that the virus 
is fully capable of utilizing human host machinery to begin replication; and though 
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the rate is not as efficient as in a native host, it is sufficient enough to induce cell 
death and cytokine expression in carcinoma transformed cells. 
 
REFERENCES 
 
 
Buccambusco, M.  (2005).  Kinetic analysis of bluetongue viral mRNA by 
quantitative real-time polymerase chain reaction.  In “A Kinetic Analysis of 
Bluetongue Virus Messenger RNA and Protein” (M. Buccambusco, ed.), 
pp. 16-54.  Utah State University Press, Logan, UT. 
 
Fillmore, G. C., Lin, H., and Li, J. K. –K. (2002).  Localization of the single-
stranded RNA-binding domains of bluetongue virus nonstructural protein 
NS2.  J. Virol. 76, 499-506. 
 
Hayama, E., and Li, J. K. –K.  (1994).  Mapping and characterization of antigenic 
epitopes and the nucleic acid-binding domains of the VP6 protein of 
bluetongue viruses.  J. Virol. 68, 3604-3611. 
 
Kowalik, T. F., Yang, Y. –Y., and Li, J. K. –K.  (1990).  Molecular cloning and 
comparative sequence analyses of bluetongue virus S1 segments by 
selective synthesis of specific full-length DNA copies of ds-RNA genes.  
Virology 177, 820-823. 
 
Li, J. K. –K., and Yang, Y. -Y.  (1990).  Mapping of two immunodominant 
antigenic epitopes conserved among the major inner capsid protein, VP7 
of five bluetongue viruses.  Virology 178, 552-559. 
 
Mertens, P. P., and Sangar, D. V.  (1985).  Analysis of the terminal sequences of 
the genome segments of four orbiviruses.  Prog. Clin. Biol. Res. 178, 371-
387. 
 
Roy, P.  (1989).  Bluetongue virus genetics and genome structure.  Virus Res. 
13, 179-206. 
 
Verwoerd, D. W.  (1970).  Failure to demonstrate in vitro as opposed to in vivo 
transcription of the bluetongue virus genome.  Onderstepoort J. Vet. Res. 
37, 225-227. 
 
Watanabe, Y. (2004).  Fifty years of interference.  Nat. Immunol. 5, 1193. 
 
Xiao, A.T., Dong, C. Y., Li, J. K. -K., Chen, D. E., Liu, J., and Zhang, W. Y.  
(2004).  Studies on the infectivity of bluetongue virus strain HbC3 to 
several human and animal tumor cells.  Virologica Sinica 19, 349-352. 
  99 
CHAPTER 4 
CELLULAR RESPONSES TO BLUETONGUE VIRUS INFECTION DO NOT 
INCLUDE ACTIVATION OF NFκB, P38 MAPK, OR JAK-STAT SIGNALING 
 
ABSTRACT 
 
BTV causes cell death and cytokine expression in human carcinoma 
transformed cells.  The magnitude of cell death and cytokine expression are a 
function of the cell’s response to infection, not a direct result of viral replication.  
Our objective was to determine the contributions of major apoptotic and 
inflammatory signaling molecules to the observed cell death and cytokine 
expression.  Our hypothesis was that the cell promotes apoptosis by 
dephosphorylating PBK and induces cytokine expression through activation of 
NFκB and p38 MAPK signaling.  PKB, NFκB, MAPK family, and tyrosine kinase 
signaling contributions were all determined by selective inhibition of signaling 
activity.  Phosphorylation levels of PKB and MAPK family members were 
subsequently measured by ELISA.   
Inhibition of PKB, NFκB, and MAPK activity all had no effect on cell death 
or cytokine expression though PKB and p38 MAPK were both constitutively 
phosphorylated in A498 and A549 cells.  Phosphorylation of PKB and p38 MAPK 
was subsequently lost upon infection with BTV.  Tyrosine kinase signaling was 
found to be involved in both cell death and cytokine expression, involving EGFR, 
but not JAK-STAT signaling.  A 35 kDa tyrosine phosphorylated protein with 
multiple phosphorylation states was isolated by two-dimensional gel 
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electrophoresis, though the identity of the protein remains unknown.  We 
conclude that conventional pro-inflammatory signaling through NFκB, p38 MAPK, 
and JAK-STAT are not involved in BTV-induced cell death and cytokine 
expression, but that PKB, EGFR, and an unknown tyrosine kinase pathway are 
involved. 
 
INTRODUCTION 
 
In previous chapters, bluetongue virus (BTV) was shown to infect human 
carcinoma transformed cells, resulting in cytokine expression and cell death.  
Cell death and cytokine expression were not the direct result of viral infection, but 
the result of the cell’s response to infection.  Even though the virus is fully 
replicating its genome in each cell line, cell death and cytokine expression were 
markedly disproportionate.  This data suggested that host defense mechanisms 
are involved, though the data does not match up exactly with literature for any 
specific process (Mahalingam et al., 1999; Nociari et al., 2007).  The fact that 
each cell line produced the same cytokine pattern and that cell death compared 
between cell lines directly correlated with the magnitude of cytokine expression 
suggested the same mechanisms are acting in each cell line and that cell death 
and cytokine expression are related through intracellular signaling. 
PKB was chosen for this study because prior studies by our lab suggested 
changes in PKB signaling occur during viral infection.  The MAPK family was 
chosen because of its role in apoptosis, inflammation, and innate immunity.  In 
addition, Chiang et al. (2006) demonstrated activation of p38 MAPK signaling 
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during BTV infection of human primary endothelial cells.  We also tested NFkB 
and tyrosine kinase signaling because of their involvement in inflammation and 
innate immunity.  These various signaling molecules represent a broad spectrum 
of potential signaling molecules involved in the cell’s response to infection.   The 
objective of this investigation was to determine the involvement of these signaling 
molecules in the human carcinoma transformed cell’s response to BTV infection.  
Our hypothesis was that the cell responds to infection by dephosphorylating PKB 
and by activating both NFκB and p38 MAPK signaling. 
 
MATERIALS AND METHODS 
 
Cell Culture 
Five cell lines were used in this study, including BHK-21 baby hamster 
kidney cells, A498 human kidney cells, HEP-G2 human liver cells, A549 human 
lung epithelial cells, and Vero African green monkey kidney cells (American Type 
Culture Collection, Manassas, VA).  Designated CCL-10, HTB-4, HB-8065, CCL-
185, and CRL-1587, respectively by the American Type Culture Collection. Each 
cell line was propagated in 75 cm2 flasks seeded at 1X106 cells and cultured in 
MEM/EBSS plus 10% FBS (Hyclone, Logan, UT) under a 5% CO2 atmosphere.  
 
BTV Stock Propagation 
Original stocks were triple plaque purified and stored frozen in aliquots 
(Kowalik et al., 1990; Li and Yang, 1990). Seed virus was prepared by infecting 
BHK-21 cells with frozen viral stock. Cells were infected at 80% confluency and 
harvested by scraping three days post infection (P.I.). After scraping, cells were 
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pelleted, washed, resuspended in fresh media, then gently sonicated three times 
using a VirSonic 50 sonicator (VirTis Inc., Gardiner, NY) prior to 0.22 μm filter 
sterilization. Viral titer was determined by plaque assay, using Vero cell 
monolayers (Hayama and Li, 1994; Fillmore et al., 2002;). Mock infections were 
similarly prepared using uninfected BHK-21 cells. 
 
Plate Preparation and BTV Infection 
96-well plates were seeded one day prior to experimentation in 
MEM/EBSS plus 10% FBS (Hyclone Laboratories, Logan, UT), such that the 
culture was approximately 50% confluent when starting the experiment. Prior to 
experimentation, plates were rinsed with MEM/EBSS. BTV infection occurred at 
an MOI of 1 using BTV serotype 17. Mock infections were performed using a 
comparable volume of uninfected BHK-21 cells, prepared as described above. 
Plates were incubated at 37 °C under 5% CO2 in MEM/EBSS plus 5% FBS. 
 
Neutral Red Staining 
A 0.034% solution of neutral red (Fisher Scientific, Fairlawn, NJ) in saline 
was prepared and filter sterilized. Immediately before use, the solution was 
diluted to 0.011% in MEM/EBSS. All media was removed from the plate, 200 
mcL of the 0.011% neutral red solution was added, and plates were incubated at 
37 °C under 5% CO2 for two hours. Plates were then rinsed once with PBS, and 
neutral red was extracted by adding 100 μg/mL neutral red extraction buffer (1:1 
ratio of Sorensen citrate buffer [0.1 M sodium citrate (Sigma, St. Louis, MO) and 
0.1 M hydrochloric acid (Fisher Scientific, Fairlawn, NJ)] and absolute ethanol 
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(Pharmco-AAPER, Brookfield, CT). Absorbance at 540 nm was read using a 
SpectraMax Plus384 microplate reader (Molecular Devices, Sunnydale, CA). 
 
Determination of Phosphorylated PKB Expression 
Rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, 
Danvers, MA) was deposited onto the bottom of a 96-well plate in a defined 
location using a Genomic Solutions (Ann Arbor, MI) non-contact printing 
machine.  Samples collected previously were diluted into cell lysis buffer (Cell 
Signaling Technologies, Danvers, MA) with 1 mM PMSF (Sigma, St. Louis, MO).  
Cells were then sonicated on ice 3 times for 10 seconds each using VirSonic 50 
sonicator (Virtis Inc., Gardiner, NY), and clarified by centrifugation.  Supernatant 
was incubated on the 96-well plates at room temperature on a lab rotator set at 
120 RPM for 1 hour.  Following TBST wash, plates were incubated with 
biotinylated mouse anti-phospho-AKT1 antibody (Cell signaling technologies, 
Danvers, MA) diluted in 5% BSA.  Binding was detected by horse radish 
peroxidase (HRP) conjugated streptavidin (Biolegend Inc., San Diego, CA) 
diluted in 5% BSA and subsequently visualized with Pierce chemiluminescent 
substrate (Rockford, IL) on an Alpha Innotec 8900 gel documentation system 
(San Leandro, CA).  Luminescent signal intensity was quantified using software 
provided with the Alpha Innotec camera. 
 
Determination of Phosphorylated p44/42  
MAPK and p38α MAPK Expression 
Cell pellets, collected previously, were processed and subsequently 
assayed for expression with the PathScan Inflammation 4-plex array (Cell 
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Signaling Technologies, Danvers, MA) according to the manufacturer’s 
recommended protocol.  
 
Determination of Phosphorylated SAPK/JNK 
Expression 
Cell pellets, collected previously, were processed and subsequently 
assayed for expression with the PathScan Phospho-SAPK/JNK (Thr183/Tyr185) 
Sandwich ELISA Kit (Cell Signaling Technologies, Danvers, MA) according to the 
manufacturer’s recommended protocol. 
 
Activity Inhibition of p38 MAPK, ERK-1/2,  
SAPK/JNK, and NFκB 
 
P38 MAPK kinase activity inhibitor SB-203580, the MEK-1/2 kinase 
activity inhibitor U-0126, SAPK/JNK kinase activity inhibitor SP600125, and 
NFκB activity inhibitor QNZ were acquired from Biomol International, Inc. 
(Plymouth Meeting, PA). Each was reconstituted to 2 mg/mL in DMSO (Sigma, 
St. Louis, MO) and tested at a final concentration of 1 μg/mL in MEM/EBSS plus 
5% FBS. Each inhibitor stock was stored at -20 °C in DMSO when not in use, 
and working solutions were prepared immediately before use. Cells were seeded 
into 96-well plates as described previously. Inhibitor was loaded into each well 
and then either mock-infected, BTV-infected, treated with 1 μg/mL, or treated 
with 50 μg/mL of polyinosinic:polycytidylic acid (poly I:C) (n=4). Supernatant was 
harvested three days P.I., and the plates stained with neutral red. 
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Activity Inhibition of Tyrosine Kinase Families 
General tyrosine kinase activity inhibitor Genistein, the Src kinase activity 
inhibitor PP2, JAK2, JAK3, and STAT-3 inhibitor AG490, platelet derived growth 
factor receptor (PDGFR) kinase activity inhibitor AG1278, and epidermal growth 
factor receptor (EGFR) kinase activity inhibitor AG1478 were acquired 
(Calbiochem, San Diego, CA).  Each was reconstituted in DMSO and tested at a 
final concentration of 1 μg/mL in MEM/EBSS plus 5% FBS. Each inhibitor stock 
was stored at -20 °C in DMSO when not in use, and working solutions were 
prepared immediately before use. Cells were seeded into 96-well plates as 
described previously. Inhibitor was loaded into each well and either mock-
infected, BTV-infected, treated with 1 μg/mL, or treated with 50 μg/mL of poly I:C 
(n=4). Supernatant was harvested three days P.I., and the plates stained with 
neutral red. 
 
Quantitation of Secreted Analyte Expression 
Supernatant samples, collected previously and stored at -80 °C, were 
thawed at room temperature. Cytokines were detected by multiplex 
immunoassay (Quansys Biosciences, Logan, UT). Samples were tested for: IL-
1α, IL-1β, IL-6, IL-8, IFNγ, TNFα, MCP-1, and RANTES. The chemiluminescent 
signal was detected using an Alpha Innotech 8900 Gel Documentation System 
(San Leandro, CA). Plates were exposed for one minute, and signal intensity was 
quantified using software provided by Alpha Innotech. 
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Tyrosine Phosphorylation by Western Blot 
Cell samples were diluted in Lameli buffer and protein concentration 
determined using the BCA method.  After titration, samples were adjusted to a 
final concentration of 500 μg/mL in Lameli buffer, 2-ME added to each sample, 
and boiled for 10 minutes.  Samples were then electrophoresed on 10% 
polyacrylamide, and electrophoretically transferred to polyvinylidene fluoride 
(PVDF) membrane (12V 1A 90 min).  Membranes were blocked with 5% BSA for 
30 minutes.  The PVDF membrane was incubated overnight at 4 oC with gentle 
shaking in 5% BSA containing Cell Signaling Technologies (Danvers, MA) 
biotinylated anti-phospho-tyrosine mouse monoclonal antibody.  Antibody binding 
was detected by incubating the membrane with HRP-labeled streptavidin for 2 
hours at room temperature with gentle shaking.  Binding was visualized with TMB 
membrane substrate (Sigma, St. Louis, MO). 
 
Two-Dimensional Gel Electrophoresis 
Samples were prepared by diluting cells in water and boiling for 10 
minutes followed by dilution into isoelectric focusing (IEF) rehydration buffer (8 M 
Urea, 2% CHAPS, and 50 mM DTT), and incubated at room temperature for 5 
minutes.  Samples were then clarified by centrifugation to remove the bulk of the 
genomic DNA and insoluble particulates.  The supernatant was applied to Bio-
Rad Laboratories (Hercules, CA) ReadyStripTM IPG strips, and allowed to actively 
rehydrate for 12 hours.  IEF was performed on the Bio-Rad Protean IEF cell 
apparatus.  After focusing, IPG strips were reduced with DTT (6 M Urea, 0.375 M 
Tris pH 8.8, 2% SDS, 20% glycerol, 2% w/v DTT) and free cysteines acetylated 
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with iodoacetamide (6 M Urea, 0.375 M Tris pH 8.8, 2% SDS, 20% glycerol, 
2.5% w/v iodoacetamide).  Samples were then electrophoresed on 10% 
polyacrylamide.  Mini gels were run at 100 volts 20 mA for 1 to 2 hours, while 
large gels were run at 150 to 300 volts 100 mA for 5-7 hours.  After completion of 
the run, gels to be stained were incubated overnight with Coomassie blue stain 
(Sigma, St. Louis, MO).  Gels to be transferred to PVDF were treated according 
to the protocols described for phospho-tyrosine Western blotting. 
 
Mass Spectroscopy 
Proteins resolved by two dimensional gel electrophoresis were excised 
from Coomassie blue stained gels.  In gel trypsin digestion and mass analysis of 
digested peptides was performed by the Utah State University Center for 
Integrated Biosystems mass spectroscopy lab (Logan, UT). 
 
Statistical Analysis 
P-values were calculated in Excel (Microsoft Corporation, Redmond, WA) 
using two-tailed Student’s t-test. 
 
RESULTS 
 
Inhibition of PKB Activity Does Not Affect 
Cell Death or Cytokine Expression 
 
PKB plays a key role in cell survivability and BTV infection leads to 
reduced survival rates in infected cells.  To examine the contribution of PKB 
phosphorylation to cell death and cytokine expression, PKB activity in A498, 
HEP-G2, A549, and Vero cells was inhibited using Triciribine (n=4).  Triciribine 
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treatment resulted in no significant change in cell death compared to untreated 
cells (Fig. 4-1 through 4-4).  Triciribine treatment also had no significant effect on 
cytokine expression.  Fig. 4-5 through 4-8 compare cytokine expression from 
mock-infected, BTV-infected, and poly I:C treated cells.  Our hypothesis was that 
even though Triciribine alone did not affect cell death or cytokine expression, 
Triciribine would contribute to cell death and cytokine expression in BTV-infected 
cells.  While BTV-infected and poly I:C treated cells showed statistically 
significant increases in cell death and cytokine expression compared to mock 
infections, Triciribine treatment had no influence on the dependent variables (Fig. 
4-1 through 4-8).  
 
Inhibition of NFκB Does Not Affect Cell 
Death or Cytokine Expression 
 
Using the same experimental design as used in PKB inhibition, cells were 
treated with QNZ inhibitor to block NFκB activity.  NFκB plays an important role 
in both apoptosis and inflammation, by promoting cell survival while 
simultaneously inducing transcription of multiple pro-inflammatory cytokines and 
chemokines (Ghosh and Hayden, 2008).  When cells were treated with QNZ, 
however, no significant change in cell death or  cytokine expression occurred as 
observed in Fig. 4-1 through 4-8. 
 
Inhibition of MAPK Signaling Does Not  
Affect Cell Death or Cytokine Expression 
 
Using the same experimental design as used in PKB inhibition, MAPK 
signaling was inhibited.  There are three groups in the MAPK family of signaling 
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molecules:  p38 MAPK, ERK-1/2, and SAPK/JNK.  Each group has separate 
functions but all have an important role either in cell viability or inflammation.  
Interestingly, none of the inhibitors resulted in a significant change in cell death 
as shown in Fig. 4-9 through 4-12.  Though BTV and poly-I:C-induced cell death 
compared with mock- infected cells, the inhibitors given singly had no influence 
on cell death.  Likewise, MAPK family inhibition had no effect on cytokine 
expression.  Fig. 4-13 through 4-16 show cytokine expression from A498 cells.  
Comparisons between inhibitors is similar in HEP-G2, A549, and Vero cells (data 
not shown). 
FIGURE 4-1.  Percent viability of A498 cells treated with Triciribine or QNZ 3 days P.I. 
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FIG. 4-1.  Percent viability of A498 cells treated with Triciribine or 
QNZ 3 days P.I.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Viability was determined by neutral red staining 3 
days P.I. 
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FIGURE 4-2.  Percent viability of HEP-G2 cells treated with Triciribine or QNZ 3 days P.I.
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FIG. 4-2.  Percent viability of HEP-G2 cells treated with Triciribine or 
QNZ 3 days P.I.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Viability was determined by neutral red staining 3 
days P.I.  
FIGURE 4-3.  Percent viability of A549 cells treated with Triciribine or QNZ 3 days P.I.
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FIG. 4-3.  Percent viability of A549 cells treated with Triciribine or 
QNZ 3 days P.I.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Viability was determined by neutral red staining 3 
days P.I. 
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FIGURE 4-4.  Percent viability of Vero cells treated with Triciribine or QNZ 3 days P.I.
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FIG. 4-4.  Percent viability of Vero cells treated with Triciribine or QNZ 
3 days P.I.  Treated cells were subsequently either mock-infected, 
BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated 
(n=4).  Viability was determined by neutral red staining 3 days P.I.  
FIGURE 4-5.  IL-6 expression from A498 cells treated with Triciribine or QNZ.
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FIG. 4-5.  IL-6 expression from A498 cells treated with either placebo, 
PKB inhibitor Triciribine, or NFκB inhibitor QNZ.  Treated cells were 
subsequently either mock-infected, BTV-infected, 1 μg/mL poly I:C 
treated, or 50 μg/mL poly I:C treated (n=4).  Cytokine expression was 
determined 3 days P.I. using supplies provided by Quansys Biosciences. 
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FIGURE 4-6.  IL-8 expression from A498 cells treated with Triciribine or QNZ.
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FIGURE 4-7.  MCP-1 expression from A498 cells treated with Triciribine or QNZ.
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FIG. 4-6.  IL-8 expression from A498 cells treated with either placebo, 
PKB inhibitor Triciribine, or NFκB inhibitor QNZ.  Treated cells were 
subsequently either mock-infected, BTV-infected, 1 μg/mL poly I:C 
treated, or 50 μg/mL poly I:C treated (n=4).  Cytokine expression was 
determined 3 days P.I. using supplies provided by Quansys Biosciences. 
FIG. 4-7. MCP-1 expression from A498 cells treated with either placebo, 
PKB inhibitor Triciribine, or NFκB inhibitor QNZ.  Treated cells were 
subsequently either mock-infected, BTV-infected, 1 μg/mL poly I:C 
treated, or 50 μg/mL poly I:C treated (n=4).  Cytokine expression was 
determined 3 days P.I. using supplies provided by Quansys Biosciences. 
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FIGURE 4-8.  RANTES expression from A498 cells treated with Triciribine or QNZ.
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FIG. 4-8.  RANTES expression from A498 cells treated with either 
placebo, PKB inhibitor Triciribine, or NFκB inhibitor QNZ.  Treated cells 
were subsequently either mock-infected, BTV-infected, 1 μg/mL poly I:C 
treated, or 50 μg/mL poly I:C treated (n=4).  Cytokine expression was 
determined 3 days P.I. using supplies provided by Quansys Biosciences.
FIGURE 4-9.   MAPK inhibitor treated A498 cell viability 3 days P.I.
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FIG. 4-9.  MAPK inhibitor treated A498 cell viability 3 days P.I. 
Cells were treated with either placebo, SB-203580, U-0126, or 
SP600125.  Treated cells were either mock-infected, BTV-
infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated 
(n=4).  Viability was determined by neutral red staining 3 days P.I. 
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FIGURE 4-10.   MAPK inhibitor treated HEP-G2 cell viability 3 days P.I.
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FIG. 4-10.  MAPK inhibitor treated HEP-G2 cell viability 3 days P.I.  
Cells were treated with either placebo, SB-203580, U-0126, or 
SP600125.  Treated cells were either mock-infected, BTV-infected, 1 
μg/mL poly I:C treated, or 50 μg/mL poly I:C treated (n=4).  Viability 
was determined by neutral red staining 3 days P.I. 
 
 
FIGURE 4-11.   MAPK inhibitor treated A549 cell viability 3 days P.I.
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FIG. 4-11.  MAPK inhibitor treated A549 cell viability 3 days P.I.  
Cells were treated with either placebo, SB-203580, U-0126, or 
SP600125.  Treated cells were either mock-infected, BTV-infected, 
1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated (n=4).  
Viability was determined by neutral red staining 3 days P.I. 
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FIGURE 4-12.   MAPK inhibitor treated Vero cell viability 3 days P.I.
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FIGURE 4-13.  IL-6 expression from MAPK inhibitor treated A498 cells 3 days P.I.
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FIG. 4-12.  MAPK inhibitor treated Vero cell viability 3 days P.I.  
Cells were treated with either placebo, SB-203580, U-0126, or 
SP600125.  Treated cells were either mock-infected, BTV-infected, 
1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated (n=4).  
Viability was determined by neutral red staining 3 days P.I. 
FIG. 4-13.  IL-6 expression from A498 cells treated with either 
placebo, p38 MAPK inhibitor SB-203580, ERK-1/2 inhibitor U-0126, 
or SAPK/JNK inhibitor SP600125.  Treated cells were subsequently 
either mock-infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 
μg/mL poly I:C treated (n=4).  Cytokine expression was determined 
3 days P.I. using supplies provided by Quansys Biosciences. 
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FIGURE 4-14.  IL-8 expression from MAPK inhibitor treated A498 cells 3 days P.I.
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FIGURE 4-15.  MCP-1 expression from MAPK inhibitor treated A498 cells 3 days P.I.
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FIG. 4-14.  IL-8 expression from A498 cells treated with either 
placebo, p38 MAPK inhibitor SB-203580, ERK-1/2 inhibitor U-0126, or 
SAPK/JNK inhibitor SP600125.  Treated cells were subsequently 
either mock-infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 
μg/mL poly I:C treated (n=4).  Cytokine expression was determined 3 
days P.I. using supplies provided by Quansys Biosciences. 
 
 
FIG. 4-15.  MCP-1 expression from A498 cells treated with either 
placebo, p38 MAPK inhibitor SB-203580, ERK-1/2 inhibitor U-0126, 
or SAPK/JNK inhibitor SP600125.  Treated cells were subsequently 
either mock-infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 
μg/mL poly I:C treated (n=4).  Cytokine expression was determined 
3 days P.I. using supplies provided by Quansys Biosciences. 
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FIGURE 4-16.  RANTES expression from MAPK inhibitor treated A498 cells 3 days P.I.
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FIG. 4-16.  RANTES expression from A498 cells treated with either 
placebo, p38 MAPK inhibitor SB-203580, ERK-1/2 inhibitor U-0126, 
or SAPK/JNK inhibitor SP600125.  Treated cells were subsequently 
either mock-infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 
μg/mL poly I:C treated (n=4).  Cytokine expression was determined 
3 days P.I. using supplies provided by Quansys Biosciences.  
 
 
BTV Infection Results in Loss of PKB  
and p38 MAPK Phosphorylation in vitro 
 
Previous experiments showed that neither PKB, NFκB, p38 MAPK, ERK-
1/2, nor SAPK/JNK inhibition had any affect on cell death or cytokine expression.  
However, preliminary Western blots (data not shown) and current literature on 
MAPK (Chiang et al., 2006) suggested both PKB and the MAPK family had 
involvement in BTV-induced cytokine expression.  Therefore, PKB and MAPK 
phosphorylation levels were directly measured in A498, HEP-G2, and A549 cells 
to ensure inhibitor functionality three days P.I. and determine if lack of activity 
was a result of changes in downstream signaling.   
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None of the tested cell lines constitutively expressed phosphorylated ERK-
1/2, while HEP-G2 cells did not express phosphorylated PKB or phosphorylated 
p38 MAPK.  All of the cell lines expressed phosphorylated SAPK/JNK, while 
A498 and A549 cells expressed both phosphorylated PBK and phosphorylated 
p38 MAPK as shown in Fig. 4-17 and 4-18, respectively. 
Interestingly, phosphorylation of both PKB and p38 MAPK declined 
significantly to near background levels when cells were infected with BTV as 
shown in Fig. 4-17 and 4-18.  Poly I:C treatment did not have an effect on A549 
cells, though there was a significant decline in PKB phosphorylation in poly I:C 
treated A498 cells, though not to levels observed during BTV-infection.  Resting 
primary cells do not constitutively express phosphorylated PKB or any of the 
MAPKs, but are phosphorylated upon infection with BTV or upon treatment with 
poly I:C in vitro (Chiang et al., 2006).  The herein observed levels of 
phosphorylated PKB and p38 MAPK are likely a consequence of the 
transformation by carcinoma, and the subsequent decline in p38 MAPK 
phosphorylation along with the lack of corresponding IL-1 and TNFα expression 
represents a clear distinction between infection of primary cells and carcinoma 
cells.  
 
Inhibition of Tyrosine Kinase Activity Does 
Not Affect BTV-Induced Cell Death 
 
Using the same experimental design as used in PKB inhibition, cells were 
treated with five different inhibitors of tyrosine kinase activity.  AG1296 and 
AG1478 directly inhibit receptor tyrosine kinases, PP2 and AG490 inhibit 
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receptor associated tyrosine kinases, and Genistein is a pan tyrosine kinase 
activity inhibitor.  Each has a major role in tyrosine based signal transduction.   
Fig. 4-19 through 4-22 show the effects of each tyrosine kinase inhibitor on A498, 
HEP-G2, A549, and Vero cell viability, respectively. 
Viability in the four cell lines was unaffected by treatment with inhibitors 
alone.  Likewise, BTV-induced cell death was unaffected in A498, HEP-G2, and 
Vero cells.  A549 cell viability, however, declined as a result of Genistein 
treatment (Fig. 4-21). 
When cells were treated with poly I:C instead of BTV, the tyrosine kinase 
activity inhibitors protected the A498 cells from poly-I:C-induced cell death.  This 
was only observed in A498 cells because they are the only cells which lose 
viability in the presence of poly I:C.  In A498 cells, four of five tyrosine kinase 
inhibitors provided protection from poly-I:C-induced cell death (Fig. 4-19). 
FIGURE 4-17.  PKB phosphorylation levels in A498 and A549 cells 3 days P.I.
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 FIG. 4-17.  Phosphorylation levels of PKB Ser473 in A498 and 
A549 cells.  Cells were either mock-infected, BTV-infected, or poly 
I:C treated (n=6).  S/N ratios were determined 3 days P.I. using 
supplies provided by Quansys Biosciences. 
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FIGURE 4-18.  p38 MAPK phosphorylation levels in A498 and A549 cells 3 days P.I.
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FIG. 4-18.  Phosphorylation levels of p38 MAPK at Thr180/Tyr182 in 
A498 and A549 cells.  Cells were either mock-infected, BTV-infected, 
or poly I:C treated (n=6).  S/N ratios were determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
 
Findings were followed up on by testing poly I:C in the presence of each 
tyrosine kinase inhibitor treated in a dose dependent manner.  As observed 
before, A498 cells were affected by tyrosine kinase activity inhibition, as shown in 
Fig. 4-23 through 4-27.  BTV-induced cell death was not protected by treatment 
with any of the inhibitors while all the inhibitors provided some protection from 
poly-I:C-induced cell death.  Though all of the tyrosine kinase inhibitors were 
cytotoxic, every poly-I:C-treated curve experienced a rise in cell viability with 
treatment concentration before falling as a result of cytotoxicity.  The most 
effective was Genistein, the general tyrosine kinase inhibitor where treatment at 
>3.2 μg/mL resulted in full protection from poly-I:C-induced cell death. 
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FIGURE 4-19.  Tyrosine kinase inhibitor treated A498 cell viability 3 days P.I.
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FIGURE 4-20.  Tyrosine kinase inhibitor treated HEP-G2 cell viability 3 days P.I.
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FIG. 4-19.  Tyrosine kinase inhibitor treated A498 cell viability 3 
days P.I.  Vero cells treated were with either placebo, pan tyrosine 
kinase inhibitor Genistein, Src inhibitor PP2, JAK-STAT inhibitor 
AG490, PDGFR inhibitor AG1296, or EGFR inhibitor AG1478.  
Treated cells were either mock-infected, BTV-infected, 1 μg/mL 
poly I:C treated, or 50 μg/mL poly I:C treated (n=4).  Viability was 
determined by neutral red staining 3 days P.I. 
 
 
FIG. 4-20.  Tyrosine kinase inhibitor treated HEP-G2 cell 
viability 3 days P.I.  Vero cells treated were with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src 
inhibitor PP2, JAK-STAT inhibitor AG490, PDGFR inhibitor 
AG1296, or EGFR inhibitor AG1478.  Treated cells were 
either mock-infected, BTV-infected, 1 μg/mL poly I:C 
treated, or 50 μg/mL poly I:C treated (n=4).  Viability was 
determined by neutral red staining 3 days P.I. 
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FIGURE 4-21.  Tyrosine kinase inhibitor treated A549 cell viability 3 days P.I.
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FIG. 4-21.  Tyrosine kinase inhibitor treated A549 cell viability 3 
days P.I.  Vero cells treated were with either placebo, pan 
tyrosine kinase inhibitor Genistein, Src inhibitor PP2, JAK-STAT 
inhibitor AG490, PDGFR inhibitor AG1296, or EGFR inhibitor 
AG1478.  Treated cells were either mock-infected, BTV-infected, 
1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated (n=4).  
Viability was determined by neutral red staining 3 days P.I. 
 
 
 
 
FIGURE 4-22.  Tyrosine kinase inhibitor treated Vero cell viability 3 days P.I.
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FIG. 4-22.  Tyrosine kinase inhibitor treated Vero cell viability 3 
days P.I.  Vero cells treated were with either placebo, pan tyrosine 
kinase inhibitor Genistein, Src inhibitor PP2, JAK-STAT inhibitor 
AG490, PDGFR inhibitor AG1296, or EGFR inhibitor AG1478.  
Treated cells were either mock-infected, BTV-infected, 1 μg/mL 
poly I:C treated, or 50 μg/mL poly I:C treated (n=4).  Viability was 
determined by neutral red staining 3 days P.I. 
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FIGURE 4-23.  Genistein treated A498 cells 3 days P.I.
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FIGURE 4-24.  PP2 treated A498 cells 3 days P.I.
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FIG. 4-23.  Genistein treated A498 cells 3 days P.I.  A498 cells 
were treated with pan tyrosine kinase inhibitor Genistein in a dose 
dependent manner.   Treated cells were either mock-infected, 
BTV-infected, or 50 μg/mL poly I:C (n=4) treated.  Viability was 
determined by neutral red staining 3 days P.I. 
 
 
FIG. 4-24.  PP2 treated A498 cells 3 days P.I.  A498 cells were 
treated with Src inhibitor PP2 in a dose dependent manner.   
Treated cells were either mock-infected, BTV-infected, or 50 
μg/mL poly I:C (n=4) treated.  Viability was determined by neutral 
red staining 3 days P.I. 
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FIGURE 4-25.  AG490 treated A498 cells 3 days P.I.
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FIG. 4-25.  AG490 treated A498 cells 3 days P.I.  A498 cells were
treated with JAK-STAT inhibitor AG490 in a dose dependent 
manner.   Treated cells were either mock-infected, BTV-infected, 
or 50 μg/mL poly I:C (n=4) treated.  Viability was determined by 
neutral red staining 3 days P.I. 
 
FIGURE 4-26.  AG1296 treated A498 cells 3 days P.I.
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FIG. 4-26.  AG1296 treated A498 cells 3 days P.I.  A498 cells 
were treated with PDGFR inhibitor AG1296 in a dose dependent 
manner.   Treated cells were either mock-infected, BTV-infected, 
or 50 μg/mL poly I:C (n=4) treated.  Viability was determined by 
neutral red staining 3 days P.I. 
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FIGURE 4-27.  AG1478 treated A498 cells 3 days P.I.
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FIG. 4-27.  AG1478 treated A498 cells 3 days P.I.  A498 cells 
were treated with EGFR inhibitor AG1478 in a dose dependent 
manner.   Treated cells were either mock-infected, BTV-infected, 
or 50 μg/mL poly I:C (n=4) treated.  Viability was determined by 
neutral red staining 3 days P.I. 
Genistein and AG1478 Treatment Reduces 
Cytokine Expression from Poly I:C-Treated, 
but Not BTV-Infected Cells 
 
In addition to measuring cell viability during treatments with tyrosine 
kinase inhibitors, cytokines were measured 3 days P.I.  None of the tyrosine 
kinase inhibitors were found to significantly reduce resting cell cytokine 
expression, but Genistein treatment did significantly reduce cytokine expression 
from BTV-infected A549 cells, though Genistein also exacerbated BTV-induced 
cell death suggesting that the decline in cytokine expression was a result of 
fewer viable cells.  BTV-infected Vero cells were also affected by tyrosine kinase 
inhibition, most notably from Genistein, but also from Src and EGFR inhibitors.  
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Cytokine expression from BTV-infected A498 and HEP-G2 cells was unaffected 
by treatment with Genistein or any other tyrosine kinase inhibitor.   
Unlike BTV-infected cells, Genistein and AG1478 consistently reduced 
cytokine expression from poly-I:C-treated A498, A549, and Vero cells as shown 
in Fig. 4-28 through 4-39.  This reduction suggests the involvement of EGFR 
signaling in the cell’s response to dsRNA and may also lead to cell death in some 
cell lines. 
 
Tyrosine Phosphorylation is Activated  
During Infection with BTV 
 
Previous testing demonstrated that tyrosine kinase signaling can have an 
influence on cell death and cytokine expression in human carcinoma transformed 
FIGURE 4-28.  IL-6 expression from tyrosine kinase inhibitor treated A498 cells 3 days P.I.
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FIG. 4-28.  IL-6 expression from A498 cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
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FIGURE 4-29.  IL-8 expression from tyrosine kinase inhibitor treated A498 cells 3 days P.I.
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FIG. 4-29.  IL-8 expression from A498 cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
 
cells.  Inhibition of signaling resulted in both protection from poly-I:C-induced cell 
death in A498 cells, and reduced cytokine expression in each cell line.  To 
identify changes in tyrosine signaling during infection, Western blots were 
performed on both mock-infected and BTV-infected human carcinoma 
transformed cells.  Fig. 4-40 and 4-41 are Western blots using anti-BTV17 
antiserum and mouse anti phosphorylated-tyrosine monoclonal antibodies, 
respectively.  There are distinct bands in Fig. 4-41 present only in BTV-infected 
cells indicating the presence of a tyrosine phosphorylated protein present only in 
BTV-infected cells (indicated by an arrow in Fig. 4-41).  Band intensity was the 
strongest in HEP-G2 cells followed by A549 cells and not resolvable in A498  
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FIGURE 4-30.  MCP-1 expression from tyrosine kinase inhibitor treated A498 cells 3 days P.I.
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FIG. 4-30.  MCP-1 expression from A498 cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
 
cells.  The bands in Fig. 4-41 were comparable in molecular weight to bands 
identified in Fig. 4-40 as probable BTV protein (compare to Fig. 4-40), with the 35 
kDa band the most prominent. 
Following these findings, each tyrosine kinase inhibitor tested previously 
was tested for its ability to prevent phosphorylation of the band identified in the 
above mentioned Western blot.  HEP-G2 cells were selected for the study 
because band intensity was strongest in these cells.  Cells were cultured in the 
presence of each MAPK inhibitor or each tyrosine kinase activity inhibitor and 
BTV.  Three days P.I., cells were harvested and assayed by Western blot for 
phosphorylated tyrosine (Fig. 4-42).  Phosphorylation of the 35 kDa protein 
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FIGURE 4-31.  RANTES expression from tyrosine kinase inhibitor treated A498 cells 3 days 
P.I.
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FIG. 4-31.  RANTES expression from A498 cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
remained in samples treated with MAPK inhibitors but was reduced by treatment 
with all tyrosine kinase inhibitors.  Genistein, the general tyrosine kinase activity 
inhibitor was the most effective at inhibiting phosphorylation of 35 kDa protein but 
all tyrosine kinase activity inhibitors resulted in noticeable reductions in band 
intensity. 
 
Unknown Tyrosine Phospho-Protein is a 35  
kDa Protein Displaying Multiple Isoelectric 
Points Between 6.5 and 7.5 
 
In addition to identifying the tyrosine kinase signaling pathways that can influence 
phosphorylation of the 35 kDa protein, two dimensional gel electrophoresis was 
performed to isolate the unknown protein.  BTV-infected and mock-infected A549 
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FIGURE 4-32.  IL-6 expression from tyrosine kinase inhibitor treated A549 cells 3 days P.I.
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FIG. 4-32.  IL-6 expression from A549 cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
 
 
cells were harvested three days P.I. from T75 flasks.  Proteins from each sample 
were separated by two-dimensional gel electrophoresis and stained with 
Coomassie blue.  Fig. 4-43 is the mock-infected sample without the 35 kDa spots 
(area where spots should be is indicated by an arrow), and Fig. 4-44 is the BTV-
infected sample with 35 kDa spots indicated by the arrow.  Replicate gels were 
blotted onto PVDF membrane and phosphorylated tyrosine containing proteins 
identified.  Spots on the gel of the BTV-infected A549 cells were found near a 
molecular weight of 35 kDa, which correlated to the subject bands on Fig. 4-41.  
The 35 kDa protein displayed multiple isoelectric points between 6.5 and 7.5.   
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FIGURE 4-33.  IL-8 expression from tyrosine kinase inhibitor treated A549 cells 3 days P.I.
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FIG. 4-33.  IL-8 expression from A549 cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
 
The spot with an isoelectric point of approximately 7.3 was the most 
intense and was excised for MALDI-TOF mass spectroscopic analysis.  Peptide 
fragment molecular weights identified by MALDI-TOF mass spectroscopy can be 
seen in Fig. 4-45.  Comparisons against known peptide fragment databases did 
not yield any credible predictions as to the identity of the unknown protein.   
Though the identity of the 35 kDa protein remains unknown, the protein 
clearly displays multiple charge states, possibly the result of multiple 
phosphorylation sites.  Testing also indicates that this 35 kDa protein is 
phosphorylated by a kinase capable of inhibition by multiple inhibitors or possibly 
can be phosphorylated by multiple tyrosine kinases. 
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FIGURE 4-34.  MCP-1 expression from tyrosine kinase inhibitor treated A549 cells 3 days P.I.
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FIG. 4-34.  MCP-1 expression from A549 cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
 
 
 
DISCUSSION 
 
 BTV was recently shown in human cells to replicate selectively in 
cancerous cells (Xiao et al., 2004).  Understanding the mechanisms through 
which BTV causes cell death may provide new avenues of research and potential 
targets in the treatment of cancer.  Chapter 2 demonstrated the involvement of 
cellular apoptotic and inflammatory pathways.  The objective of this study was to 
determine the involvement of key inflammatory and apoptotic signaling molecules 
in BTV-induced cell death in carcinoma transformed cells. 
 
  
  133 
FIGURE 4-35.  RANTES expression from tyrosine kinase inhibitor treated A549 cells 3 days 
P.I.
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FIG. 4-35.  RANTES expression from A549 cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
 
 
The signaling molecule PKB was first explored because of its involvement 
in regulating cell survival.  It is a known proto-oncogene, over-phosphorylated in 
various cancers, along with its upstream and downstream signaling molecules 
(Yuan and Cantley, 2008).  We hypothesized the carcinoma transformed cell 
responds to BTV infection by shutting down PKB related signaling leading to cell 
death.  Testing revealed phosphorylated PKB in mock-infected A498 and A549 
cells, but not in HEP-G2 cells.  Subsequent infection with BTV resulted in 
complete loss of phosphorylation while poly I:C treatment did not affect the level 
of phosphorylation.  The observations for A498 and A549 cells is consistent with 
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FIGURE 4-36.  IL-6 expression from tyrosine kinase inhibitor treated Vero cells 3 days P.I.
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FIG. 4-36.  IL-6 expression from Vero cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly I:C 
treated (n=4).  Cytokine expression was determined 3 days P.I. using 
supplies provided by Quansys Biosciences. 
the hypothesis, though testing with PKB inhibitor, Triciribine, demonstrated that a 
loss of PKB phosphorylation alone is not sufficient to cause cell death.  Triciribine 
treatment in mock-infected cells had no effect on cell death in any of the tested 
cell lines, indicating that additional signals are required to cause cell death.   
BTV clearly supplies these additional signals during infection, possibly as 
a result of viral replication.  BTV’s genome is dsRNA which can activate an 
innate immune response to the dsRNA, which can lead to cell death in primary 
and carcinoma transformed cells (Zhang and Samuel, 2007).  Our hypothesis 
was that the reductions in phosphorylated PKB during BTV infection made it 
possible for dsRNA-induced pro-apoptotic signals to proceed.  To test this, 
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FIGURE 4-37.  IL-8 expression from tyrosine kinase inhibitor treated Vero cells 3 days P.I.
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FIG. 4-37.  IL-8 expression from Vero cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
Triciribine treated cells were also treated with poly I:C.  However, inhibition of 
PKB phosphorylation by Triciribine had no effect on poly-I:C-induced cell death 
(Fig. 4-1 to 4-4) disproving our hypothesis and indicating that BTV was also 
activating non-PKB, non-dsRNA related apoptotic pathways. 
In addition to activating apoptosis, BTV also activates pro-inflammatory 
signaling pathways as evidenced by the expression of cytokine and chemokines 
during infection.  Double stranded RNA activates the same or similar pro- 
inflammatory signaling pathways leading to expression of the same cytokines 
and chemokines (Chapter 2), suggesting it was possible that apoptosis and 
cytokine expression were activated through the same signaling procedure.  One 
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FIGURE 4-38.  MCP-1 expression from tyrosine kinase inhibitor treated Vero cells 3 days P.I.
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FIG. 4-38.  MCP-1 expression from Vero cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
signaling molecule involved in both inflammation and apoptosis is nuclear 
translocation factor kappa B (NFκB).  NFκB plays a central role in inflammatory 
signaling in nearly all cells.  Activation, however, leads to expression of 
interleukin 1 (IL-1) and tumor necrosis factor alpha (TNFα), in addition to the 
cytokines observed in Chapter 2.  NFκB also promotes cell survival when 
activated.  The lack of IL-1 and TNFα as well as the presence of apoptosis 
suggested NFκB was probably not involved during BTV infection.   
NFκB involvement was tested using the inhibitor QNZ.  BTV-infected and 
poly-I:C-treated cells were both treated with QNZ, and subsequently measured 
for cell death and cytokine expression (Fig. 4-1 through 4-8).  NFκB was found to 
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FIGURE 4-39.  RANTES expression from tyrosine kinase inhibitor treated Vero cells 3 days P.I.
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FIG. 4-39.  RANTES expression from Vero cells treated with either 
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2, 
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR 
inhibitor AG1478.  Treated cells were subsequently either mock-
infected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly 
I:C treated (n=4).  Cytokine expression was determined 3 days P.I. 
using supplies provided by Quansys Biosciences. 
 
 
have no influence on the observed cell death or cytokine expression, indicating 
that BTV-induced cell death and cytokine expression involves either signaling 
through non-NFκB mediated pathways or other pathways are compensating for 
the inhibited NFκB pathway.  The observed cytokines are known to be activated 
by multiple pathways leading us to conclude that NFκB signaling is not involved 
in the cell’s response to BTV infection. 
 One potential alternative pathway was MAPK signaling.  MAPK signaling 
can lead to cytokine expression very similar to NFκB signaling.  In addition, 
studies in human primary cells showed that BTV activates p38 MAPK during 
infection leading to the expression of cytokines (Chiang et al., 2006).  Normal  
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FIG. 4-40.  Western blot using anti-BTV17 antisera.  Mock-infected and BTV-
infected A498, HEP-G2, or A549 cells were harvested 3 days P.I., protein 
concentration adjusted to 500 μg/mL, ran on a 10% polyacrylamide gel, blotted 
to PVDF membrane and stained with rabbit anti-BTV17 antisera.  Column (1) 
Bio-Rad prestained protein marker with weights indicated in kilodaltons, (2) 
mock-infected A498 cells, (3) BTV-infected A498 cells, (4) mock-infected HEP-
G2 cells, (5) BTV-infected HEP-G2 cells, (6) mock-infected A549 cells, (7) BTV-
infected A549 cells.  Arrows indicate bands present only in BTV-infected 
samples. 
p38 MAPK-induced cytokine expression, however, includes Il-1 and 
TNFα expression which are not observed in any of the tested human carcinoma 
transformed cells, suggesting that if the pathway is also activated in transformed 
cells, it is not functioning properly.  ERK-1/2 and SAPK-JNK pathways were both  
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FIG. 4-41.  Western blotusing anti-phospho tyrosine antibodies.  Mock-
infected and BTV-infected A498, HEP-G2, or A549 cells were harvested 3 
days P.I., protein concentration adjusted to 500 μg/mL, ran on a 10% 
polyacrylamide gel, blotted to PVDF membrane and stained with rabbit anti-
BTV17 antisera.  Column (1) Bio-Rad prestained protein marker with weights 
indicated in kilodaltons, (2) mock-infected A498 cells, (3) BTV-infected A498 
cells, (4) mock-infected HEP-G2 cells, (5) BTV-infected HEP-G2 cells, (6) 
mock-infected A549 cells, (7) BTV-infected A549 cells.  Arrows indicate 
bands present only in BTV-infected samples. 
tested along with p38 MAPK for involvement during BTV infection and during 
poly I:C treatment.  cell death or cytokine expression.  Further testing revealed 
that p38 MAPK was constitutively phosphorylated in A498 and A549 cells, but is 
subsequently de-phosphorylated upon infection with BTV.  A surprising 
observation that is markedly different from primary cells.  P38 MAPK is not 
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Inhibition of p38 MAPK, ERK-1/2, and SAPK/JNK all had no significant effect on 
phosphorylated in mock- infected primary cells but is phosphorylated upon 
infection with BTV.  This observation reveals p38 MAPK is a key differentiator 
between some primary and carcinoma transformed cells.  The observation also 
suggests either that p38 MAPK signaling requires other signals to lead to 
cytokine expression or that the p38 MAPK signaling pathway is broken 
downstream of p38 MAPK in carcinoma transformed cells. 
FIG. 4-42.    Western blot of BTV-infected, inhibitor treated, HEP-G2 cells 
harvested 3 days P.I.  Column (1) Bio-Rad prestained protein marker with 
weights indicated in kilodaltons, (2) Placebo, (3) SB-203580, (4) U-1026, (5) 
SP600125, (6) Genistein, (7) PP2, (8) AG490, (9) AG1296, (10) AG1478.  
Protein concentration was adjusted to 500 μg/mL, ran on a 10% polyacrylamide 
gel, blotted to PVDF membrane and stained with mouse anti-phos-tyrosine 
antibodies.  Arrow indicates 35 kDa tyrosine phosphorylated protein bands. 
ERK-1/2 and SAPK/JNK were also tested for level of phosphorylation.  
ERK-1/2 was not phosphorylated in mock-infected or BTV-infected cells, while 
SAPK/JNK was constitutively phosphorylated in mock-infected cells but remained 
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FIG. 4-43.    Coomassie blue stained gel of mock-infected 
A549 cells 3 days P.I.  Sample protein concentration was 
adjusted to 500 μg/mL, ran on a 10% polyacrylamide gel and 
subsequently stained with Coomassie blue.  Arrow indicates 
the location where the 35 kilodalton protein displaying 
isoforms between 6.5 and 7.5 pI should be found. 
 
unaffected by infection with BTV.  Given the lack of a significant change in 
phosphorylation combined with no significant change in cell death or cytokine 
expression during inhibitor treatment, we concluded that ERK-1/2 and SAPK/JNK 
signaling are not involved in the cell’s response to BTV-infection.  P38 MAPK 
signaling on the other hand is significantly affected by infection with BTV, 
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FIG. 4-44.    Coomassie blue stained gel of BTV-infected 
A549 cells 3 days P.I.  Sample protein concentration was 
adjusted to 500 μg/mL, ran on a 10% polyacrylamide gel and 
subsequently stained with Coomassie blue.  Arrow indicates 
the location where the 35 kilodalton protein displaying 
multiple isoforms between 6.5 and 7.5 pI . 
 
suggesting that altered p38 MAPK signaling plays a central role in cell 
transformation and BTV-oncotrophism.  DeMaula et al. (2001) demonstrated that 
in bovine endothelial cells expressed greater levels of IL-1, IL-6, and TNFα 
relative to ovine endothelial cells which correlated with higher viral titers but less 
severe disease and pathology.  The elevated expression indicates greater 
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FIG. 4-45.  MALDI-TOF mass spectroscopy analysis of a 35 kDa protein 
isolated from BTV-infected A549 cells 3 days P.I.  The ~7.3 pI isoform of the 
35 kDa protein identified in Fig. 4-44 was excised from the polyacrylamide gel 
and was subject to in gel trypsin digestion.  The unknown protein is a tyrosine 
phosphorylated protein displaying multiple isoelectric points. 
activation of the NFκB and p38 MAPK pathways, as is also found in human 
primary endothelial cells.  Greater activation of these pathways leads to reduced 
apoptosis, which in vivo reduces hemorrhage, and the corresponding coagulation 
and necrosis.  However, in the tested carcinoma transformed cell lines, these 
pathways are not activated, as evidenced by the lack of IL-1 and TNFα 
expression, and are therefore not protected from apoptosis. 
Though p38 MAPK signaling was affected by BTV-infection and may play 
an important role in preventing apoptosis and promoting IL-1 and TNFα 
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expression from primary cells, it is not the pathway through with cytokine 
expression occurs in carcinoma transformed cells.  To further explore the 
signaling pathways utilized by carcinoma cells to induce apoptosis and cytokine 
expression, tyrosine kinase signaling was tested.  Tyrosine kinase signaling is 
best known for its role in conveying extracellular signals through receptor 
tyrosine kinases (RTKs), though tyrosine kinase signaling is utilized by many 
systems including innate immunity.  For example, type I interferons signal 
through  the JAK-STAT pathway, which involves tyrosine kinase signaling 
(Schindler and Plumlee, 2008).  To determine tyrosine kinase signaling 
involvement during infection, the profile of tyrosine phosphorylated proteins in 
BTV-infected cells were compared with mock-infected cells (Fig. 4-41).  This 
Western blot suggested there was at least one protein selectively tyrosine 
phosphorylated during BTV-infection.  These findings led us to acqure a panel of 
tyrosine kinase inhibitors.  Each inhibitor was reduced to levels which were not 
cytotoxic and studies performed with mock-infected, BTV-infected, and poly-I:C-
treated cells.  None of the inhibitors were shown to have a significant impact on 
cell death or cytokine expression in mock-infected cells.  BTV-infected cells also 
were not significantly affected by tyrosine kinase inhibition, except for A549 and 
Vero cells wherein Genistein, the general tyrosine kinase inhibitor, caused an 
increase in cell death.  If a tyrosine kinase signaling pathway were conveying 
pro-inflammatory or pro-apoptotic signals, then inhibition would have protected 
the cells from death rather than increased cell death.  Instead, it may be that the 
tyrosine kinases are conveying cell survival signals, and inhibition of the signaling 
  
  145 
promoted apoptosis.  For example, EGFR and Src, two tyrosine kinases, are 
upstream activators of phosphoinositol-3-kinase (PI-3K) mediated PKB 
phosphorylation.  However, cell death was present only in the A549 and Vero 
cells indicating the increase in cell death is related only to some cell lines.  Also, 
EGFR and Src kinase inhibitors did not have the same effect indicating the 
example pathway is not the pathway being affected by Genistein.   
Unlike BTV-infected or mock-infected cells, poly-I:C-treated cells were 
affected by tyrosine kinase inhibition.  A498 cells were protected from poly-I:C-
induced cell death, suggesting that A498 cells respond to poly I:C through 
tyrosine kinase signaling.  Interestingly, all of the tyrosine kinase inhibitors 
partially protected A498 cells from poly-I:C-induced cell death, suggesting that 
the inhibitors all cross inhibit the same pathway.   
Poly-I:C-treated HEP-G2, A549, and Vero cell viability were unaffected by 
tyrosine kinase inhibition, but cytokine expression was affected.  A498, A549, 
and Vero cells all showed reductions in cytokine expression during tyrosine 
kinase inhibition.  The reductions were most prevalent in Genistein and AG1478 
treated cells.  AG1478 inhibits EGFR signaling which may be related to the 
reduction in PKB signaling shown previously during BTV infection.  PKB 
involvement and the changes in cytokine expression observed during AG1478 
treatment suggest some EGFR involvement during BTV-infection, possibly part 
of the innate immune response.  In addition, cell death and cytokine expression 
from poly-I:C-treated cells may utilize the same signaling pathway(s), but 
protection from cell death is only observed in A498 cells because these cells are 
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the only ones in which poly I:C induced cell death.  However, the more significant 
tyrosine kinase inhibitor is Genistein, which suggests that there remains 
additional tyrosine kinases, apart from the four major families tested, which are 
involved in both cell death and cytokine expression. 
After determining the effect each inhibitor had on cell death and cytokine 
expression, each inhibitor was used to determine the identity of the tyrosine 
phosphorylated protein observed in Fig. 4-41.  HEP-G2 cells were treated with 
each tyrosine kinase inhibitor and each MAPK inhibitor and then tested for 
changes in phosphorylation of the 35 kDa protein by Western blot.  MAPK 
inhibitors were tested along with tyrosine kinase activity inhibitors because MAPK 
activation involves tyrosine phosphorylation in the activation site and needed to 
be excluded.  Fig. 4-42 demonstrated, that in HEP-G2 cells, phosphorylation of 
the unknown protein was inhibited by every tested tyrosine kinase inhibitor, but 
not the MAPK inhibitors.  Indicating that the unknown protein is not one of the 
MAPK proteins.  The pathway of phosphorylation could not be determined as 
hoped, but instead suggests the observed protein is phosphorylated by a tyrosine 
kinase that can be inhibited by many compounds.  The same conclusion was 
made from the A498 poly I:C data, raising the possibility that the same pathway 
that is protecting A498 cells from poly-I:C-induced death is the same protein 
identified here in HEP-G2 cells.  This protein, however, was weakly 
phosphorylated in A498 cells and BTV-induced cell death is not protected by 
inhibition of this protein. 
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In an effort to identify the unknown protein and its function, BTV-infected 
and mock-infected A549 cells were resolved by two-dimensional gel 
electrophoresis.  One set was stained with Coomassie blue (Fig. 4-43 and 4-44), 
and the other set was transferred to PVDF and tyrosine phosphorylated proteins 
determined by Western blot.  The unknown tyrosine phosphorylated protein was 
found to be about 35 kDa in size and had multiple isoelectric points suggesting 
multiple phosphorylation states.  The protein, however, could not be identified by 
mass spectroscopy leaving no answer to its function. 
Findings in Chapter 2 suggested that cell death and cytokine expression 
were directly related.  We hypothesized that this relationship was through 
conserved intracellular signaling.  Our objective was to determine the role of key 
apoptotic and pro-inflammatory signaling molecules in the cell’s response to BTV 
infection.  We conclude that both PKB and p38 MAPK play a role in 
transformation of the A498 and A549, but not HEP-G2 cell lines and that BTV 
induced cell death by inactivating these pathways.  The inactivation of p38 MAPK 
during infection is one distinguishing characteristic of BTV infection of carcinoma 
transformed cells compared with BTV-infected human primary cells, and explains 
the lack of IL-1 and TNFα expression and the increased rate of apoptosis of 
carcinoma transformed cells relative to primary cells. 
Other MAPK family members were not affected by BTV infections, but 
tyrosine kinase signaling is involved.  BTV infection leads to increased tyrosine 
phosphorylation.  This tyrosine signaling promotes cell death in A498 cells, 
promotes cell survival in BTV-infected A549 and Vero cells, and promotes 
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cytokine expression in A498, A549, and Vero cells.  Tyrosine signaling 
involvement in cell death is highly variable between cell lines but utilizes a 
signaling pathway that is capable of cross inhibition by multiple classes of kinase 
inhibitors.  Cytokine signaling occurs through both an unknown pathway and 
partially through EGFR signaling.  The unknown pathway involved in cytokine 
expression may be the same pathway involved in cell death.  Western blotting 
suggests this pathway involves a 35 kDa protein with multiple phosphorylation 
states, though the pathway remains unknown.  However, this pathway does not 
involve PDGFR signaling or JAK-STAT signaling, and therefore does not involve 
type I interferon signaling.  The other two conventional inflammatory pathways, 
p38 MAPK and NFκB are also not involved, leaving the mechanism by which 
carcinoma transformed cells respond to BTV infection distinct from primary cells 
and independent of conventional inflammatory pathways.  BTV selectively kills 
carcinoma transformed cells because their cellular response to BTV infection 
does not include activation of NFκB, p38 MAPK, or JAK-STAT signaling.  
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CHAPTER 5 
 
SUMMARY AND CONCLUSION 
 
 
SUMMARY 
 
Bluetongue virus (BTV) is a dangerous pathogen to ruminants recently re-
emerging in epidemic form in Europe, but it is BTV’s effects in human carcinoma 
transformed cells that is the subject of this study.  In ruminants, like sheep, BTV 
causes bluetongue disease, a hemorrhagic disease that is often fatal.  However, 
BTV does not cause disease in humans and the population remains largely 
seronegative, suggesting that not only are humans not compatible hosts, but that 
we don’t usually get infected.  However, BTV will infect human cells in vitro.  
When primary cultures are infected, viral RNA can be detected but there is no 
cell death, though BTV will cause cell death in carcinoma transformed cells.   
The study objectives were to determine infectivity of BTV serotype 17 in 
three human cell lines, quantify cell death and cytokine expression, and 
determine the involvement of key intracellular signaling molecules in the 
observed cell death and cytokine expression.  First, BTV was found to induce cell 
death in all three human cell lines.  Cell death was most significant in A498 cells 
followed by A549 cells and last by HEP-G2 cells (Fig. 2-3).  Cytokine expression 
from the same cells was subsequently found elevated in all cell lines upon 
infection with BTV (Table 2-1).  Cytokine expression is the cell’s primary means 
of communication with the immune system and consequently the expression 
profile provides great insight into the cell’s response to infection.  Multiplex 
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cytokine testing methods were employed to examine multiple cytokines (25 in 
total).  Four cytokines were found elevated upon infection, including IL-6, IL-8, 
MCP-1, and RANTES.  All are pro-inflammatory cytokines which are expressed 
constitutively by cancer cells and naturally expressed by damaged or stressed 
cells.  Cytokine production directly correlated with cell death between the cell 
lines which suggested that cell death and cytokine expression were both 
activated through the same signaling cascade, and that all three human cell lines 
utilized this same pathway.  Our hypothesis was that this signaling pathway was 
activated by innate immunity’s response to BTV generated dsRNA. 
To understand the involvement of innate immunity in viral induced 
inflammation and cell death, studies were repeated with polyinosinic:poly-
cytosinic acid (poly I:C) treated cells.  Poly I:C is a synthetic dsRNA molecule 
known to induce anti-dsRNA responses in vitro and in vivo.  Studies following a 
similar procedure in primary lung endothelial cells found that synthetic dsRNA 
could induce cytokine expression and p38 MAPK phosphorylation commensurate 
with BTV infection.  However, poly I:C treatment in human carcinoma 
transformed cells had no detectable effect on cell death in HEP-G2, A549, and 
Vero cells, and only resulted in cell death in A498 cells at abnormally high 
concentrations of poly I:C (Fig. 2-4).  Poly I:C could induce cytokine expression in 
A498, A549, and Vero cells, though cytokine expression did not include IL-1 and 
TNFα as was seen in primary cells.   
Viral RNA and protein expression were subsequently measured in each 
cell line.  Our objective was to determine the relative extent of replication 
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between cell lines.  Our hypothesis was that cell death and cytokine expression 
were directly related to viral replication.  However, RNA expression from BTV 
was highest in A498 cells generating concentrations statistically indistinguishable 
from BHK-21 cells, while BTV generated the lowest concentrations of RNA in 
A549 cells.  Surprisingly, viral protein expression did not directly correlate with 
RNA expression and was inversely proportionate, between cell lines, with cell 
death and cytokine expression.  The data did not support the initial hypothesis, 
but suggested that cell death and cytokine expression are a function of the cell’s 
ability to detect and respond to infection rather than the virus rate of replication. 
Protein and RNA studies in conjunction with cell death and cytokine 
testing suggested that the host cell is quickly recognizing the infection in a cell 
line dependent manner and is activating pro-apoptotic pathways.  To better 
understand the intracellular events taking place, we acquired inhibitors to a 
number of signaling molecules central to inflammation and apoptosis.  These 
included protein kinase B (PKB), p38 mitogen-activated protein kinase (p38 
MAPK), extracellular signal regulated kinase (ERK-1/2), stress activated protein 
kinase (SAPK/JNK), nuclear translocating factor kappa B (NFκB), and the major 
tyrosine kinase families.  The respective proteins were inhibited in mock-infected, 
BTV-infected, and poly I:C treated cells.  However, only the tyrosine kinase 
inhibitors had any appreciable effect on cell death, which was observed only in 
poly I:C treated A498, and BTV-infected A549 cells. The tyrosine kinase 
inhibitors were also the only inhibitors to reduce cytokine expression.  The effects 
  153 
 
were most overt with the pan-tyrosine kinase inhibitor and the endothelial growth 
factor receptor (EGFR) inhibitor. 
Inhibition studies suggested that none of the tested signaling proteins 
were singly involved in cell death or cytokine expression.  It was expected that if 
there was involvement, there would have been differences in either cell death or 
cytokine expression upon treatment. 
In addition to the inhibition studies, phosphorylation of PKB, p38 MAPK, 
ERK-1/2, and SAPK/JNK were directly measured.  These direct measurements 
confirmed that the inhibitors were functioning, as the level of phosphorylation 
diminished in the presence of the respective inhibitor, thereby validating the 
results of the inhibition studies.  Direct measurements also revealed that A498 
and A549 cells constitutively expressed active (phosphorylated) PKB; but when 
infected with BTV, phosphorylation was inhibited.  It was hypothesized that BTV 
reduced phosphorylation of PKB by activating alternate pro-apoptotic 
mechanisms; and that this dephosphorylation permitted normal apoptotic 
mechanisms to take place.  However, there was no detectable change in cell 
death when uninfected cells were treated with PKB inhibitor suggesting that 
dephosphorylation of AKT alone is not sufficient to induce apoptosis.   
P38 MAPK was also found to be constitutively phosphorylated in mock-
infected cells.  This level of phosphorylation is consistent with transformation by 
carcinoma, as p38 MAPK phosphorylation leads to protection from apoptosis.  In 
these cells, infection with BTV caused p38 MAPK dephosphorylation.  Prior 
studies found that p38 MAPK was not phosphorylated in primary cells, but then 
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phosphorylated during BTV infection.  This phosphorylation lead to IL-1 and 
TNFα expression, which is not seen in carcinoma transformed cells.  These 
discrepancies in p38 MAPK phosphorylation suggest that lack of functional p38 
MAPK signaling in carcinoma transformed cells may be a primary reason for 
BTV’s oncotrophism.  Other MAPK family members: ERK-1/2 and JNK were also 
tested for changes in phosphorylation upon infection, but were not significantly 
affected.   
Lack of NFκB or p38 MAPK involvement in cytokine expression suggested 
possible involvement of tyrosine kinase signaling.  Innate immunity to dsRNA is 
known to signal through tyrosine kinase signaling pathways, such as the Janus 
kinase (JAK-STAT) signaling pathway.  Western blots using anti-phosphorylated 
tyrosine antibodies suggested that there was differential tyrosine phosphorylation 
between mock-infected and BTV-infected cells.  One specific 35 kDa protein in 
BTV-infected cells was particularly phosphorylated.  The tyrosine kinase 
inhibitors were all tested for their ability to phosphorylate this protein in HEP-G2 
cells.  Cells were treated with each tyrosine kinase and MAPK inhibitor and the 
proteins stained by Western blot with anti-phospho-tyrosine antibodies three 
days P.I.  Surprisingly, each tyrosine kinase inhibitor caused a reduction in 
phosphorylation on the unknown protein, suggesting that the unknown protein is 
phosphorylated by a kinase to which many different inhibitors function.  The 
identity of the protein could not be determined by mass spectroscopy but the 
inhibition of phosphorylation combined with the lack of changes in cell death or 
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cytokine expression in HEP-G2 cells during inhibitor treatment indicates that the 
35 kDa protein is not integrally involved in the cell’s response to infection. 
 
CONCLUSION 
 
BTV is a dangerous ruminant pathogen which does not naturally cause 
disease in humans, but is capable of infecting and killing human carcinoma cells 
in vitro while simultaneously inducing an immune response from the infected cell.  
The cellular immune response includes the production of pro-inflammatory 
cytokines and chemokines followed by apoptosis.  The key differences in 
infection between carcinoma cells and primary endothelial cells includes 
extensive cell death in carcinoma cells; lack of IL-1 and TNFα expression; 
constitutive PKB and p38 MAPK phosphorylation, which is subsequently lost 
upon infection; and a lack of poly I:C inducible cytokine expression or p38 MAPK 
phosphorylation.   
Cytokine production and cell death are the product of the cell recognizing 
and responding to infection.  Hence, greater cell death correlates with reduced 
viral protein production.  Both apoptosis and cytokine expression are related 
through intracellular signaling.  The cell responds to infection by activating 
tyrosine kinase signaling leading to cytokine expression through a non-NFκB 
pathway and subsequently dephosphorylating PKB and p38 MAPK, leading to 
apoptosis.  Tyrosine kinases, PKB, and p38 MAPK are all related through EGFR 
signaling shown here to affect cytokine production and may be the primary cause 
of cell death, cytokine expression, and p38 MAPK dysfunction. 
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We conclude that BTV can infect many types of cells, including primary 
and carcinoma transformed cells, but that BTV-induced cell death is a function of 
the cell’s response to infection and is therefore cell dependent.  Carcinoma 
transformed cells are susceptible to cell death because they do not respond to 
infection through  NFκB or p38 MAPK signaling which traditionally leads to 
protection from apoptosis.  As a result, when a carcinoma cell is infected with 
BTV, the virus is recognized by innate immunity and responds by expressing 
cytokines and subsequently inducing apoptosis. 
 
FUTURE RESEARCH 
 
This study focused entirely on cells transformed by carcinoma.  Future 
studies would involve direct comparisons between primary epithelial cells and 
carcinoma transformed  cells.  Additionally, p38-MAPK was  shown to be 
dephosphorylated during BTV infection, contrary to observations in primary cells.  
We would want to inhibit p38 MAPK phosphorylation in primary cells, and inhibit 
p38 MAPK dephosphorylation in carcinoma cells to determine the contribution 
p38 MAPK signaling has on cell survival.  Similar testing should also be done 
with NFκB. 
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